In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned entity1_term, thereby excluding the possibility that the p76 entity2_term is a previously undescribed splice variant of the cloned IL-7R.
IL-7R
IL-7R
0
These analyses showed that the ability of PBMC to proliferate to entity1_term correlated with expression of the entity2_term IL-7R, and not with expression of the p90 IL-7R.
IL-7
p76
0
These analyses showed that the ability of PBMC to proliferate to entity1_term correlated with expression of the p76 entity2_term, and not with expression of the p90 IL-7R.
IL-7
IL-7R
0
These analyses showed that the ability of PBMC to proliferate to entity1_term correlated with expression of the p76 IL-7R, and not with expression of the entity2_term IL-7R.
IL-7
p90
0
These analyses showed that the ability of PBMC to proliferate to entity1_term correlated with expression of the p76 IL-7R, and not with expression of the p90 entity2_term.
IL-7
IL-7R
0
These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the entity1_term entity2_term, and not with expression of the p90 IL-7R.
p76
IL-7R
0
These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the entity1_term IL-7R, and not with expression of the entity2_term IL-7R.
p76
p90
0
These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the entity1_term IL-7R, and not with expression of the p90 entity2_term.
p76
IL-7R
0
These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 entity1_term, and not with expression of the entity2_term IL-7R.
IL-7R
p90
0
These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 entity1_term, and not with expression of the p90 entity2_term.
IL-7R
IL-7R
0
In addition, PCR analysis of entity1_term-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R, thereby excluding the possibility that the entity2_term IL-7R is a previously undescribed splice variant of the cloned IL-7R.
p76
p76
0
In addition, PCR analysis of entity1_term-expressing cells could not detect splicing of the extracellular domain of the cloned entity2_term, thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned IL-7R.
p76
IL-7R
0
These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 IL-7R, and not with expression of the entity1_term entity2_term.
p90
IL-7R
0
These antibodies also immunoprecipitated the cloned entity1_term as a 90-kDa species from both 125-I-surface-labeled resting and activated T cells, but were unable to precipitate the 76-kDa entity2_term.
IL-7R
IL-7R
0
In addition, PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned entity1_term, thereby excluding the possibility that the entity2_term IL-7R is a previously undescribed splice variant of the cloned IL-7R.
IL-7R
p76
0
entity1_term-driven proliferation is mediated via high affinity entity2_term, and accordingly, Scatchard analysis revealed that, like the p90 IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.
IL-7
IL-7R
0
entity1_term-driven proliferation is mediated via high affinity IL-7R, and accordingly, Scatchard analysis revealed that, like the entity2_term IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.
IL-7
p90
0
IL-7-driven proliferation is mediated via high affinity entity1_term, and accordingly, Scatchard analysis revealed that, like the entity2_term IL-7R, the p76 IL-7R bound IL-7 with dual (high; Kd 38 pM and low; Kd 360 pM) affinity.
IL-7R
p90
0
In agreement, mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the entity1_term entity2_term.
p76
IL-7R
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/entity1_term, and TRAFs) associated with both of the entity2_term and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.
MACH
p60
1
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/entity1_term, and TRAFs) associated with both of the p60 and entity2_term forms of the TNF receptor and with other members of the TNF receptor superfamily.
MACH
p80
1
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, entity1_term/MACH, and TRAFs) associated with both of the entity2_term and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.
FLICE
p60
1
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, entity1_term/MACH, and TRAFs) associated with both of the p60 and entity2_term forms of the TNF receptor and with other members of the TNF receptor superfamily.
FLICE
p80
1
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/entity1_term, RIP, FLICE/MACH, and TRAFs) associated with both of the entity2_term and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.
MORT
p60
1
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/entity1_term, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and entity2_term forms of the TNF receptor and with other members of the TNF receptor superfamily.
MORT
p80
1
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (entity1_term, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and entity2_term forms of the TNF receptor and with other members of the TNF receptor superfamily.
TRADD
p80
1
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, entity1_term/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the entity2_term and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.
FADD
p60
1
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (entity1_term, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the entity2_term and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.
TRADD
p60
1
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, entity1_term, FLICE/entity2_term, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.
RIP
MACH
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, entity1_term/entity2_term, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.
FLICE
MACH
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (entity1_term, FADD/MORT, RIP, FLICE/entity2_term, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.
TRADD
MACH
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/entity1_term, RIP, FLICE/entity2_term, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.
MORT
MACH
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, entity1_term/MORT, RIP, FLICE/entity2_term, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.
FADD
MACH
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, entity1_term, FLICE/MACH, and TRAFs) associated with both of the entity2_term and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.
RIP
p60
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the entity1_term and entity2_term forms of the TNF receptor and with other members of the TNF receptor superfamily.
p60
p80
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, entity1_term, entity2_term/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.
RIP
FLICE
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/MORT, entity1_term, FLICE/MACH, and TRAFs) associated with both of the p60 and entity2_term forms of the TNF receptor and with other members of the TNF receptor superfamily.
RIP
p80
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (entity1_term, FADD/MORT, entity2_term, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.
TRADD
RIP
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/entity1_term, entity2_term, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.
MORT
RIP
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, entity1_term/MORT, entity2_term, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.
FADD
RIP
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (entity1_term, FADD/MORT, RIP, entity2_term/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.
TRADD
FLICE
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, FADD/entity1_term, RIP, entity2_term/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.
MORT
FLICE
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, entity1_term/MORT, RIP, entity2_term/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.
FADD
FLICE
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, entity1_term/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and entity2_term forms of the TNF receptor and with other members of the TNF receptor superfamily.
FADD
p80
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (entity1_term, FADD/entity2_term, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.
TRADD
MORT
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (entity1_term, entity2_term/MORT, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.
TRADD
FADD
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors (TRADD, entity1_term/entity2_term, RIP, FLICE/MACH, and TRAFs) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily.
FADD
MORT
0
We postulate that the mechanism of bone induction is based on the secretion of bone morphogenetic proteins entity1_term and entity2_term by the grafted HeLa cells.
BMP-4
BMP-6
0
entity1_term and entity2_term involvement in the osteogenic properties of the HeLa cell line.
BMP-4
BMP-6
0
A protein, sorting nexin-1 (entity1_term), was identified in a human cell line that bound to a region of the epidermal growth factor receptor (entity2_term) containing the lysosomal targeting code.
SNX1
EGFR
1
A protein, entity1_term (SNX1), was identified in a human cell line that bound to a region of the epidermal growth factor receptor (entity2_term) containing the lysosomal targeting code.
sorting nexin-1
EGFR
1
A protein, sorting nexin-1 (entity1_term), was identified in a human cell line that bound to a region of the entity2_term (EGFR) containing the lysosomal targeting code.
SNX1
epidermal growth factor receptor
1
A protein, entity1_term (SNX1), was identified in a human cell line that bound to a region of the entity2_term (EGFR) containing the lysosomal targeting code.
sorting nexin-1
epidermal growth factor receptor
1
A protein, sorting nexin-1 (SNX1), was identified in a human cell line that bound to a region of the entity1_term (entity2_term) containing the lysosomal targeting code.
epidermal growth factor receptor
EGFR
0
A protein, entity1_term (entity2_term), was identified in a human cell line that bound to a region of the epidermal growth factor receptor (EGFR) containing the lysosomal targeting code.
sorting nexin-1
SNX1
0
entity1_term contains a region of homology to a yeast vacuolar sorting protein, and overexpression of SNX1 decreased the amount of entity2_term on the cell surface as a result of enhanced rates of constitutive and ligand-induced degradation.
SNX1
EGFR
0
SNX1 contains a region of homology to a yeast vacuolar sorting protein, and overexpression of entity1_term decreased the amount of entity2_term on the cell surface as a result of enhanced rates of constitutive and ligand-induced degradation.
SNX1
EGFR
0
Thus, entity1_term is likely to play a role in sorting entity2_term to lysosomes.
SNX1
EGFR
0
entity1_term contains a region of homology to a yeast vacuolar sorting protein, and overexpression of entity2_term decreased the amount of EGFR on the cell surface as a result of enhanced rates of constitutive and ligand-induced degradation.
SNX1
SNX1
0
Enhanced degradation of entity1_term receptors by a sorting nexin, entity2_term.
EGF
SNX1
0
Enhanced degradation of entity1_term receptors by a sorting entity2_term, SNX1.
EGF
nexin
0
Enhanced degradation of EGF receptors by a sorting entity1_term, entity2_term.
nexin
SNX1
0
In addition, a possible role for entity1_term, the product of entity2_term, in atherosclerotic lesion development is put into perspective.
Gas6
growth arrest-specific gene 6
0
This overview summarizes the current knowledge on entity1_term (entity2_term) in the progression of atherosclerosis and the influence of MMPs in aneurysm formation.
plasminogen activator inhibitor-1
PAI-1
0
The splicing factor U2AF (U2 snRNP auxiliary factor) is a heterodimer with subunits of 65 and 35 kD (entity1_term and entity2_term).
U2AF65
U2AF35
1
Nuclear extracts deficient in entity1_term were inactive; however, both constitutive and enhancer-dependent splicing could be restored by the addition of purified recombinant entity2_term.
U2AF35
U2AF35
0
entity1_term binds specifically to 3' splice sites, but previous studies failed to demonstrate a function for entity2_term.
U2AF65
U2AF35
0
In vitro protein-RNA interaction studies with pre-mRNAs containing either a constitutive or regulated splicing enhancer revealed that entity1_term directly mediates interactions between entity2_term and proteins bound to the enhancers.
U2AF35
U2AF65
0
Thus, entity1_term functions as a bridge between entity2_term and the enhancer complex to recruit U2AF65 to the adjacent intron.
U2AF35
U2AF65
0
Thus, entity1_term functions as a bridge between U2AF65 and the enhancer complex to recruit entity2_term to the adjacent intron.
U2AF35
U2AF65
0
Thus, U2AF35 functions as a bridge between entity1_term and the enhancer complex to recruit entity2_term to the adjacent intron.
U2AF65
U2AF65
0
Furthermore, p21 blocks the ability of entity1_term to activate entity2_term, the principal replicative DNA polymerase.
PCNA
DNA polymerase delta
1
This regulation results from a direct interaction between entity1_term and entity2_term.
p21
PCNA
1
Here we use simian virus 40 DNA replication in vitro to show than entity1_term directly inhibits entity2_term-dependent DNA replication in the absence of a cyclin/CDK.
p21
PCNA
1
Furthermore, entity1_term blocks the ability of entity2_term to activate DNA polymerase delta, the principal replicative DNA polymerase.
p21
PCNA
1
In normal human cells, but not in many tumour cells, entity1_term exists in a quaternary complex with a cyclin, a CDK, and the entity2_term (PCNA).
p21
proliferating-cell nuclear antigen
1
In normal human cells, but not in many tumour cells, entity1_term exists in a quaternary complex with a cyclin, a CDK, and the proliferating-cell nuclear antigen (entity2_term).
p21
PCNA
1
The entity1_term inhibitor of cyclin-dependent kinases controls DNA replication by interaction with entity2_term.
p21
PCNA
1
The entity1_term tumour-suppressor protein controls the expression of a gene encoding the entity2_term cyclin-dependent protein kinase (CDK) regulator.
p53
p21
0
Levels of entity1_term protein are increased in senescent cells and entity2_term overexpression blocks the growth of tumour cells.
p21
p21
0
entity1_term controls CDK activity, thereby affecting cell-cycle control, whereas entity2_term functions in both DNA replication and repair.
p21
PCNA
0
In normal human cells, but not in many tumour cells, p21 exists in a quaternary complex with a cyclin, a CDK, and the entity1_term (entity2_term).
proliferating-cell nuclear antigen
PCNA
0
Furthermore, entity1_term blocks the ability of PCNA to activate entity2_term, the principal replicative DNA polymerase.
p21
DNA polymerase delta
0
Thus, during entity1_term-mediated suppression of cell proliferation, p21 and entity2_term may be important for coordinating cell-cycle progression, DNA replication and repair of damaged DNA.
p53
PCNA
0
Thus, during p53-mediated suppression of cell proliferation, entity1_term and entity2_term may be important for coordinating cell-cycle progression, DNA replication and repair of damaged DNA.
p21
PCNA
0
Thus, during entity1_term-mediated suppression of cell proliferation, entity2_term and PCNA may be important for coordinating cell-cycle progression, DNA replication and repair of damaged DNA.
p53
p21
0
Several genes are involved in this process, and two have been the focus of recent interest: the entity1_term (NRAMP1) gene and the genes coding for the entity2_term.
natural resistance-associated protein
vitamin D receptor
0
Several genes are involved in this process, and two have been the focus of recent interest: the entity1_term (entity2_term) gene and the genes coding for the vitamin D receptor.
natural resistance-associated protein
NRAMP1
0
Several genes are involved in this process, and two have been the focus of recent interest: the natural resistance-associated protein (entity1_term) gene and the genes coding for the entity2_term.
NRAMP1
vitamin D receptor
0
Positive inotropic responses mediated by endothelin entity1_term and entity2_term receptors in human myocardial trabeculae.
ET(A)
ET(B)
0
The aim of the present study was to determine possible inotropic effects mediated by endothelin entity1_term and entity2_term receptors in human myocardial trabeculae from the right atrium and the left ventricle.
ET(A)
ET(B)
0
Endothelin-1 (entity1_term) and entity2_term had a strong positive inotropic effect in all trabeculae.
ET-1
ET-3
0
entity1_term (entity2_term) and ET-3 had a strong positive inotropic effect in all trabeculae.
Endothelin-1
ET-1
0
entity1_term (ET-1) and entity2_term had a strong positive inotropic effect in all trabeculae.
Endothelin-1
ET-3
0
Preincubation with the entity1_term antagonist FR139317 (1 microM) decreased significantly (P < 0.005) the potency of entity2_term in both atrial and ventricular trabeculae, without any significant changes in Emax (maximum effect obtained with an agonist).
ET(A) receptor
ET- I
0
The entity1_term agonist IRL 1620 had a positive inotropic effect only in some trabeculae, and the entity2_term antagonist BQ 788 (1 microM) almost completely blocked this effect.
ET(B) receptor
ET(B) receptor
0
entity1_term was significantly more potent than entity2_term in both atrial (P < 0.001) and ventricular (P < 0.05) trabeculae.
ET-1
ET-3
0
These results suggest that both entity1_term and entity2_term receptors mediate positive inotropic responses at both the atrial and ventricular level in the human heart.
ET(A)
ET(B)
0
Some entity1_term substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or entity2_term in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.
HBx
RPB5
1
Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that entity1_term transactivation requires the interactions of both entity2_term and TFIIB.
HBx
RPB5
1
Our finding that entity1_term directly interacts with RNA polymerase II subunit 5 (entity2_term), a common subunit of RNA polymerases, implies that HBx directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J.
HBx
RPB5
1
Delineation of the binding regions of these three proteins revealed that entity1_term, entity2_term, and TFIIB each has two binding regions for the other two proteins.
HBx
RPB5
1
Our finding that entity1_term directly interacts with entity2_term (RPB5), a common subunit of RNA polymerases, implies that HBx directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J.
HBx
RNA polymerase II subunit 5
1
Our finding that entity1_term directly interacts with RNA polymerase II subunit 5 (RPB5), a common subunit of RNA polymerases, implies that entity2_term directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J.
HBx
HBx
0
Our finding that HBx directly interacts with entity1_term (entity2_term), a common subunit of RNA polymerases, implies that HBx directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J.
RNA polymerase II subunit 5
RPB5
0
Our finding that HBx directly interacts with entity1_term (RPB5), a common subunit of RNA polymerases, implies that entity2_term directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J.
RNA polymerase II subunit 5
HBx
0
Hepatitis B virus X protein is a transcriptional modulator that communicates with transcription factor IIB and the RNA polymerase II subunit 5. entity1_termn (entity2_term) transactivates viral and cellular genes through a wide variety of cis-elements.
Hepatitis B virus X protei
HBx
0
These results indicated that HBx is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and TFIIB through communication with entity1_term and entity2_term.
RPB5
TFIIB
0
These results indicated that HBx is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and entity1_term through communication with RPB5 and entity2_term.
TFIIB
TFIIB
0
These results indicated that entity1_term is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and TFIIB through communication with RPB5 and entity2_term.
HBx
TFIIB
0
These results indicated that HBx is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and entity1_term through communication with entity2_term and TFIIB.
TFIIB
RPB5
0
These results indicated that entity1_term is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and TFIIB through communication with entity2_term and TFIIB.
HBx
RPB5
0
These results indicated that entity1_term is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and entity2_term through communication with RPB5 and TFIIB.
HBx
TFIIB
0
Our finding that HBx directly interacts with RNA polymerase II subunit 5 (entity1_term), a common subunit of RNA polymerases, implies that entity2_term directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J.
RPB5
HBx
0
Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both entity1_term and entity2_term.
RPB5
TFIIB
0
Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that entity1_term transactivation requires the interactions of both RPB5 and entity2_term.
HBx
TFIIB
0
Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or entity1_term in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and entity2_term.
RPB5
TFIIB
0
Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either entity1_term or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and entity2_term.
TFIIB
TFIIB
0
Some entity1_term substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and entity2_term.
HBx
TFIIB
0
Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or entity1_term in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both entity2_term and TFIIB.
RPB5
RPB5
0
Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either entity1_term or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both entity2_term and TFIIB.
TFIIB
RPB5
0
Some entity1_term substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both entity2_term and TFIIB.
HBx
RPB5
0
Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or entity1_term in a mutually exclusive manner, suggesting that entity2_term transactivation requires the interactions of both RPB5 and TFIIB.
RPB5
HBx
0
Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either entity1_term or RPB5 in a mutually exclusive manner, suggesting that entity2_term transactivation requires the interactions of both RPB5 and TFIIB.
TFIIB
HBx
0
Some entity1_term substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that entity2_term transactivation requires the interactions of both RPB5 and TFIIB.
HBx
HBx
0
Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either entity1_term or entity2_term in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.
TFIIB
RPB5
0
Some entity1_term substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either entity2_term or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.
HBx
TFIIB
0
entity1_term is a transcriptional modulator that communicates with transcription factor IIB and the entity2_term.
Hepatitis B virus X protein
RNA polymerase II subunit 5
0
entity1_term is a transcriptional modulator that communicates with entity2_term and the RNA polymerase II subunit 5.
Hepatitis B virus X protein
transcription factor IIB
0
Hepatitis B virus X protein is a transcriptional modulator that communicates with entity1_term and the entity2_term.
transcription factor IIB
RNA polymerase II subunit 5
0
In this context, we examined the possibility that entity1_term and entity2_term interact with other general transcription factors.
HBx
RPB5
0
entity1_term and entity2_term specifically bound to transcription factor IIB (TFIIB) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.
HBx
RPB5
0
entity1_term and RPB5 specifically bound to entity2_term (TFIIB) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.
HBx
transcription factor IIB
0
entity1_term and RPB5 specifically bound to transcription factor IIB (entity2_term) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.
HBx
TFIIB
0
HBx and entity1_term specifically bound to entity2_term (TFIIB) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.
RPB5
transcription factor IIB
0
HBx and entity1_term specifically bound to transcription factor IIB (entity2_term) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.
RPB5
TFIIB
0
HBx and RPB5 specifically bound to entity1_term (entity2_term) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.
transcription factor IIB
TFIIB
0
Delineation of the binding regions of these three proteins revealed that entity1_term, RPB5, and entity2_term each has two binding regions for the other two proteins.
HBx
TFIIB
0
Delineation of the binding regions of these three proteins revealed that HBx, entity1_term, and entity2_term each has two binding regions for the other two proteins.
RPB5
TFIIB
0
Cross-family dimerization of transcription factors Fos/Jun and entity1_term/entity2_term alters DNA binding specificity.
ATF
CREB
1
Cross-family dimerization of transcription factors entity1_term/entity2_term and ATF/CREB alters DNA binding specificity.
Fos
Jun
1
Cross-family dimerization of transcription factors entity1_term/Jun and entity2_term/CREB alters DNA binding specificity.
Fos
ATF
0
Cross-family dimerization of transcription factors entity1_term/Jun and ATF/entity2_term alters DNA binding specificity.
Fos
CREB
0
Cross-family dimerization of transcription factors Fos/entity1_term and entity2_term/CREB alters DNA binding specificity.
Jun
ATF
0
Cross-family dimerization of transcription factors Fos/entity1_term and ATF/entity2_term alters DNA binding specificity.
Jun
CREB
0
The Fos/entity1_term and entity2_term/CREB families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes.
Jun
ATF
0
The entity1_term/entity2_term and ATF/CREB families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes.
Fos
Jun
0
The Fos/entity1_term and ATF/entity2_term families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes.
Jun
CREB
0
The entity1_term/Jun and entity2_term/CREB families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes.
Fos
ATF
0
The Fos/Jun and entity1_term/entity2_term families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes.
ATF
CREB
0
The entity1_term/Jun and ATF/entity2_term families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes.
Fos
CREB
0
Although Fos/entity1_term and entity2_term/CREB were previously thought to interact preferentially with different DNA regulatory elements (the AP-1/TRE and ATF/CRE sites, respectively), we find that members of these two families form selective cross-family heterodimers.
Jun
ATF
0
Although Fos/entity1_term and ATF/entity2_term were previously thought to interact preferentially with different DNA regulatory elements (the AP-1/TRE and ATF/CRE sites, respectively), we find that members of these two families form selective cross-family heterodimers.
Jun
CREB
0
Although entity1_term/entity2_term and ATF/CREB were previously thought to interact preferentially with different DNA regulatory elements (the AP-1/TRE and ATF/CRE sites, respectively), we find that members of these two families form selective cross-family heterodimers.
Fos
Jun
0
Although Fos/Jun and entity1_term/entity2_term were previously thought to interact preferentially with different DNA regulatory elements (the AP-1/TRE and ATF/CRE sites, respectively), we find that members of these two families form selective cross-family heterodimers.
ATF
CREB
0
Although entity1_term/Jun and entity2_term/CREB were previously thought to interact preferentially with different DNA regulatory elements (the AP-1/TRE and ATF/CRE sites, respectively), we find that members of these two families form selective cross-family heterodimers.
Fos
ATF
0
Although entity1_term/Jun and ATF/entity2_term were previously thought to interact preferentially with different DNA regulatory elements (the AP-1/TRE and ATF/CRE sites, respectively), we find that members of these two families form selective cross-family heterodimers.
Fos
CREB
0
These findings indicate that the entity1_term/entity2_term and ATF/CREB families of transcription factors are not as distinct as was previously thought.
Fos
Jun
0
These findings indicate that the entity1_term/Jun and entity2_term/CREB families of transcription factors are not as distinct as was previously thought.
Fos
ATF
0
These findings indicate that the entity1_term/Jun and ATF/entity2_term families of transcription factors are not as distinct as was previously thought.
Fos
CREB
0
These findings indicate that the Fos/entity1_term and entity2_term/CREB families of transcription factors are not as distinct as was previously thought.
Jun
ATF
0
These findings indicate that the Fos/entity1_term and ATF/entity2_term families of transcription factors are not as distinct as was previously thought.
Jun
CREB
0
These findings indicate that the Fos/Jun and entity1_term/entity2_term families of transcription factors are not as distinct as was previously thought.
ATF
CREB
0
This last observation was confirmed by affinity chromatography and immunoprecipitation, which demonstrated an interaction between entity1_term and entity2_term.
Rb
UBF
1
Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) entity1_term specifically inhibits the activity of the RNA polymerase I transcription factor entity2_term (upstream binding factor) in vitro.
Rb
UBF
1
Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) entity1_term specifically inhibits the activity of the RNA polymerase I transcription factor UBF (entity2_term) in vitro.
Rb
upstream binding factor
1
Activity of RNA polymerase I transcription factor entity1_term blocked by entity2_term gene product.
UBF
Rb
1
The protein encoded by the entity1_term (entity2_term) functions as a tumour suppressor and negative growth regulator.
retinoblastoma susceptibility gene
Rb
0
Here we report that (1) there is an accumulation of entity1_term protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of entity2_term to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.
Rb
Rb
0
Here we report that (1) there is an accumulation of entity1_term protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor entity2_term (upstream binding factor) in vitro.
Rb
UBF
0
Here we report that (1) there is an accumulation of entity1_term protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (entity2_term) in vitro.
Rb
upstream binding factor
0
Here we report that (1) there is an accumulation of entity1_term protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional entity2_term pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.
Rb
Rb
0
Here we report that (1) there is an accumulation of entity1_term protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) entity2_term specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.
Rb
Rb
0
Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of entity1_term to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor entity2_term (upstream binding factor) in vitro.
Rb
UBF
0
Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of entity1_term to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (entity2_term) in vitro.
Rb
upstream binding factor
0
Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of entity1_term to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional entity2_term pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.
Rb
Rb
0
Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of entity1_term to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) entity2_term specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.
Rb
Rb
0
Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor entity1_term (entity2_term) in vitro.
UBF
upstream binding factor
0
Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional entity1_term pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor entity2_term (upstream binding factor) in vitro.
Rb
UBF
0
Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional entity1_term pocket; and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (entity2_term) in vitro.
Rb
upstream binding factor
0
Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional entity1_term pocket; and (4) entity2_term specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro.
Rb
Rb
0
These results indicate that there is an additional mechanism by which entity1_term suppresses cell growth, namely that entity2_term directly represses transcription of the rRNA genes.
Rb
Rb
0
As entity1_term forms complexes with beta 1 integrins and the integrins are known to regulate keratinocyte behaviour, we investigated entity2_term expression and function in human epidermal keratinocytes.
CD9
CD9
0
There was extensive co-localisation of entity1_term and beta 1 integrins on microvilli and at cell-cell borders of basal keratinocytes; however, in contrast to the integrins, entity2_term was not found in focal adhesions.
CD9
CD9
0
entity1_term was detected in beta 1 integrin immunoprecipitates and also in immunoprecipitates of CD44 and entity2_term, but not of cadherins.
CD9
syndecan
0
CD9 was detected in beta 1 integrin immunoprecipitates and also in immunoprecipitates of entity1_term and entity2_term, but not of cadherins.
CD44
syndecan
0
entity1_term was associated with alpha 3 beta 1 but not alpha 5 beta 1; small amounts of entity2_term also co-immunoprecipitated with antibodies to alpha 2 beta 1 and alpha 6 beta 4.
CD9
CD9
0
entity1_term was detected in beta 1 integrin immunoprecipitates and also in immunoprecipitates of entity2_term and syndecan, but not of cadherins.
CD9
CD44
0
Antibodies to entity1_term did not affect the proportion of keratinocytes that adhered to entity2_term, type IV collagen and fibronectin, but did inhibit motility of keratinocytes on tissue culture plastic.
CD9
laminin 1
0
Antibodies to entity1_term did not affect the proportion of keratinocytes that adhered to laminin 1, entity2_term and fibronectin, but did inhibit motility of keratinocytes on tissue culture plastic.
CD9
type IV collagen
0
Antibodies to entity1_term did not affect the proportion of keratinocytes that adhered to laminin 1, type IV collagen and entity2_term, but did inhibit motility of keratinocytes on tissue culture plastic.
CD9
fibronectin
0
Antibodies to CD9 did not affect the proportion of keratinocytes that adhered to entity1_term, entity2_term and fibronectin, but did inhibit motility of keratinocytes on tissue culture plastic.
laminin 1
type IV collagen
0
Antibodies to CD9 did not affect the proportion of keratinocytes that adhered to entity1_term, type IV collagen and entity2_term, but did inhibit motility of keratinocytes on tissue culture plastic.
laminin 1
fibronectin
0
Antibodies to CD9 did not affect the proportion of keratinocytes that adhered to laminin 1, entity1_term and entity2_term, but did inhibit motility of keratinocytes on tissue culture plastic.
type IV collagen
fibronectin
0
Like antibodies to the entity1_term subunit, anti-entity2_term inhibited suspension-induced terminal differentiation.
beta 1 integrin
CD9
0
The crystal structure of the homodimeric entity1_term (entity2_term) has been determined by X-ray analysis to 3.0 A resolution.
BB isoform of human recombinant platelet-derived growth factor
PDGF-BB
0
Other NH2-terminal residues directly modulate the affinity of entity1_term dimers for the entity2_term tethering site.
RII beta
AKAP75
1
Replacement of Val20-Leu21 with Ala-Ala produced a dimeric entity1_term protein that binds entity2_term approximately 4% as avidly as wild-type RII beta.
RII beta
AKAP75
1
Mutagenesis, recombinant protein expression, and physicochemical characterization were used to investigate the structural basis for the homodimerization and entity1_term binding activities of entity2_term.
AKAP75
RII beta
1
Evidently, large hydrophobic side chains of Leu13 and Phe36 play pivotal roles in stabilizing entity1_term-entity2_term interactions.
RII beta
RII beta
1
The prototypic neuronal anchor protein entity1_term has a COOH-terminal 22-residue entity2_term binding (tethering) site.
AKAP75
RII beta
1
In neurons cAMP-dependent protein kinase II beta (entity1_term) is sequestered in the dendritic cytoskeleton because the regulatory subunit (entity2_term) of the enzyme is tightly bound by A Kinase Anchor Proteins (AKAPs).
PKAII beta
RII beta
0
In neurons entity1_term (entity2_term) is sequestered in the dendritic cytoskeleton because the regulatory subunit (RII beta) of the enzyme is tightly bound by A Kinase Anchor Proteins (AKAPs).
cAMP-dependent protein kinase II beta
PKAII beta
0
In neurons entity1_term (PKAII beta) is sequestered in the dendritic cytoskeleton because the regulatory subunit (entity2_term) of the enzyme is tightly bound by A Kinase Anchor Proteins (AKAPs).
cAMP-dependent protein kinase II beta
RII beta
0
Mutagenesis of the regulatory subunit (entity1_term) of cAMP-dependent protein kinase II beta reveals hydrophobic amino acids that are essential for RII beta dimerization and/or anchoring entity2_term to the cytoskeleton.
RII beta
RII beta
0
Mutagenesis of the regulatory subunit (RII beta) of cAMP-dependent protein kinase II beta reveals hydrophobic amino acids that are essential for entity1_term dimerization and/or anchoring entity2_term to the cytoskeleton.
RII beta
RII beta
0
Mutagenesis of the regulatory subunit (RII beta) of entity1_term reveals hydrophobic amino acids that are essential for RII beta dimerization and/or anchoring entity2_term to the cytoskeleton.
cAMP-dependent protein kinase II beta
RII beta
0
Replacement of Val20-Leu21 with Ala-Ala produced a dimeric RII beta protein that binds entity1_term approximately 4% as avidly as wild-type entity2_term.
AKAP75
RII beta
0
Replacement of Val20-Leu21 with Ala-Ala produced a dimeric entity1_term protein that binds AKAP75 approximately 4% as avidly as wild-type entity2_term.
RII beta
RII beta
0
A secondary consequence of destabilizing entity1_term dimers is the loss of intracellular targeting/anchoring capacity because monomers fail to bind entity2_term.
RII beta
AKAP75
0
Mutagenesis of the regulatory subunit (entity1_term) of cAMP-dependent protein kinase II beta reveals hydrophobic amino acids that are essential for entity2_term dimerization and/or anchoring RII beta to the cytoskeleton.
RII beta
RII beta
0
Mutagenesis of the regulatory subunit (entity1_term) of entity2_term reveals hydrophobic amino acids that are essential for RII beta dimerization and/or anchoring RII beta to the cytoskeleton.
RII beta
cAMP-dependent protein kinase II beta
0
Mutagenesis of the regulatory subunit (RII beta) of entity1_term reveals hydrophobic amino acids that are essential for entity2_term dimerization and/or anchoring RII beta to the cytoskeleton.
cAMP-dependent protein kinase II beta
RII beta
0
Substitution of Ala for Leu13 or Phe36 generates monomeric entity1_term subunits that cannot bind entity2_term.
RII beta
AKAP75
0
The results are not due to general misfolding since mutant entity1_term monomers bind cAMP and inhibit the catalytic subunit of entity2_term with the same affinity and efficacy as wild-type RII beta dimers.
RII beta
PKAII beta
0
The results are not due to general misfolding since mutant entity1_term monomers bind cAMP and inhibit the catalytic subunit of PKAII beta with the same affinity and efficacy as wild-type entity2_term dimers.
RII beta
RII beta
0
The results are not due to general misfolding since mutant RII beta monomers bind cAMP and inhibit the catalytic subunit of entity1_term with the same affinity and efficacy as wild-type entity2_term dimers.
PKAII beta
RII beta
0
Levels of p16(entity1_term) and entity2_term(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.
INK4a
p57
0
Levels of entity1_term(entity2_term) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.
p16
INK4a
0
Levels of p16(entity1_term) and p57(entity2_term) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.
INK4a
KIP2
0
Levels of p16(entity1_term) and p57(KIP2) rise in HUCs during progressive passages, whereas only entity2_term increases in HPEC cultures.
INK4a
p16
0
Levels of entity1_term(INK4a) and entity2_term(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.
p16
p57
0
Levels of p16(INK4a) and entity1_term(entity2_term) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.
p57
KIP2
0
Levels of p16(INK4a) and entity1_term(KIP2) rise in HUCs during progressive passages, whereas only entity2_term increases in HPEC cultures.
p57
p16
0
Temporally following this growth arrest, the cells develop a senescence morphology and express entity1_term (entity2_term).
senescence-associated beta-galactosidase
SA-beta-gal
0
Temporally following this growth arrest, the cells develop a senescence morphology and express senescence-associated entity1_term (entity2_term).
beta-galactosidase
SA-beta-gal
0
Levels of entity1_term(INK4a) and p57(entity2_term) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.
p16
KIP2
0
Levels of entity1_term(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only entity2_term increases in HPEC cultures.
p16
p16
0
Analysis of p53, p21(CIP1), p15(INK4b), entity1_term(entity2_term), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
p16
INK4a
0
Analysis of p53, p21(CIP1), p15(entity1_term), p16(entity2_term), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
INK4b
INK4a
0
Analysis of p53, p21(CIP1), entity1_term(INK4b), p16(entity2_term), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
p15
INK4a
0
Analysis of p53, p21(entity1_term), p15(INK4b), p16(entity2_term), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
CIP1
INK4a
0
Analysis of p53, entity1_term(CIP1), p15(INK4b), p16(entity2_term), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
p21
INK4a
0
Analysis of entity1_term, p21(CIP1), p15(INK4b), p16(entity2_term), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
p53
INK4a
0
Analysis of p53, p21(CIP1), p15(INK4b), p16(entity1_term), and entity2_term(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
INK4a
p57
0
Analysis of p53, p21(CIP1), p15(INK4b), p16(entity1_term), and p57(entity2_term) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
INK4a
KIP2
0
Analysis of p53, p21(CIP1), p15(entity1_term), entity2_term(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
INK4b
p16
0
Analysis of p53, p21(CIP1), entity1_term(INK4b), entity2_term(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
p15
p16
0
Analysis of p53, p21(entity1_term), p15(INK4b), entity2_term(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
CIP1
p16
0
Analysis of p53, entity1_term(CIP1), p15(INK4b), entity2_term(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
p21
p16
0
Analysis of entity1_term, p21(CIP1), p15(INK4b), entity2_term(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
p53
p16
0
Analysis of p53, p21(CIP1), p15(INK4b), entity1_term(INK4a), and entity2_term(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
p16
p57
0
Analysis of p53, p21(CIP1), p15(INK4b), entity1_term(INK4a), and p57(entity2_term) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
p16
KIP2
0
Analysis of p53, p21(CIP1), entity1_term(entity2_term), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
p15
INK4b
0
Analysis of p53, p21(entity1_term), p15(entity2_term), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
CIP1
INK4b
0
Analysis of p53, entity1_term(CIP1), p15(entity2_term), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
p21
INK4b
0
Analysis of entity1_term, p21(CIP1), p15(entity2_term), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
p53
INK4b
0
Analysis of p53, p21(CIP1), p15(entity1_term), p16(INK4a), and entity2_term(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
INK4b
p57
0
Analysis of p53, p21(CIP1), p15(entity1_term), p16(INK4a), and p57(entity2_term) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
INK4b
KIP2
0
Levels of p16(INK4a) and p57(entity1_term) rise in HUCs during progressive passages, whereas only entity2_term increases in HPEC cultures.
KIP2
p16
0
Analysis of p53, p21(entity1_term), entity2_term(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
CIP1
p15
0
Analysis of p53, entity1_term(CIP1), entity2_term(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
p21
p15
0
Analysis of entity1_term, p21(CIP1), entity2_term(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
p53
p15
0
Analysis of p53, p21(CIP1), entity1_term(INK4b), p16(INK4a), and entity2_term(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
p15
p57
0
Analysis of p53, p21(CIP1), entity1_term(INK4b), p16(INK4a), and p57(entity2_term) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
p15
KIP2
0
Analysis of p53, entity1_term(entity2_term), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
p21
CIP1
0
Analysis of entity1_term, p21(entity2_term), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
p53
CIP1
0
Analysis of p53, p21(entity1_term), p15(INK4b), p16(INK4a), and entity2_term(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
CIP1
p57
0
Analysis of p53, p21(entity1_term), p15(INK4b), p16(INK4a), and p57(entity2_term) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
CIP1
KIP2
0
Analysis of entity1_term, entity2_term(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
p53
p21
0
Analysis of p53, entity1_term(CIP1), p15(INK4b), p16(INK4a), and entity2_term(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
p21
p57
0
Analysis of p53, entity1_term(CIP1), p15(INK4b), p16(INK4a), and p57(entity2_term) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
p21
KIP2
0
Analysis of entity1_term, p21(CIP1), p15(INK4b), p16(INK4a), and entity2_term(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
p53
p57
0
Analysis of entity1_term, p21(CIP1), p15(INK4b), p16(INK4a), and p57(entity2_term) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
p53
KIP2
0
We find that p53, p21(CIP1) and entity1_term(entity2_term) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.
p15
INK4b
0
We find that p53, p21(entity1_term) and p15(entity2_term) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.
CIP1
INK4b
0
We find that entity1_term, p21(CIP1) and p15(entity2_term) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.
p53
INK4b
0
We find that p53, entity1_term(CIP1) and p15(entity2_term) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.
p21
INK4b
0
We find that p53, p21(entity1_term) and entity2_term(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.
CIP1
p15
0
We find that entity1_term, p21(CIP1) and entity2_term(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.
p53
p15
0
We find that p53, entity1_term(CIP1) and entity2_term(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.
p21
p15
0
We find that entity1_term, p21(entity2_term) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.
p53
CIP1
0
We find that p53, entity1_term(entity2_term) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.
p21
CIP1
0
Temporally following this growth arrest, the cells develop a senescence morphology and express entity1_termentity2_term (SA-beta-gal).
senescence-associated beta-galactosidase
beta-galactosidase
0
The induced expression of entity1_term, similar to entity2_term, produces a senescent-like phenotype.
p57
p16
0
entity1_term, entity2_term, p19(INK4d) and p27(KIP1) decrease in both cell types.
pRB
cyclin D
0
entity1_term, cyclin D, entity2_term(INK4d) and p27(KIP1) decrease in both cell types.
pRB
p19
0
entity1_term, cyclin D, p19(entity2_term) and p27(KIP1) decrease in both cell types.
pRB
INK4d
0
entity1_term, cyclin D, p19(INK4d) and entity2_term(KIP1) decrease in both cell types.
pRB
p27
0
entity1_term, cyclin D, p19(INK4d) and p27(entity2_term) decrease in both cell types.
pRB
KIP1
0
pRB, entity1_term, entity2_term(INK4d) and p27(KIP1) decrease in both cell types.
cyclin D
p19
0
pRB, entity1_term, p19(entity2_term) and p27(KIP1) decrease in both cell types.
cyclin D
INK4d
0
pRB, entity1_term, p19(INK4d) and entity2_term(KIP1) decrease in both cell types.
cyclin D
p27
0
pRB, entity1_term, p19(INK4d) and p27(entity2_term) decrease in both cell types.
cyclin D
KIP1
0
pRB, cyclin D, entity1_term(entity2_term) and p27(KIP1) decrease in both cell types.
p19
INK4d
0
pRB, cyclin D, entity1_term(INK4d) and entity2_term(KIP1) decrease in both cell types.
p19
p27
0
pRB, cyclin D, entity1_term(INK4d) and p27(entity2_term) decrease in both cell types.
p19
KIP1
0
pRB, cyclin D, p19(entity1_term) and entity2_term(KIP1) decrease in both cell types.
INK4d
p27
0
pRB, cyclin D, p19(entity1_term) and p27(entity2_term) decrease in both cell types.
INK4d
KIP1
0
pRB, cyclin D, p19(INK4d) and entity1_term(entity2_term) decrease in both cell types.
p27
KIP1
0
We find that entity1_term, entity2_term(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.
p53
p21
0
Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and entity1_term(entity2_term) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.
p57
KIP2
0
The protein entity1_term, a key mediator of mitogenesis and differentiation, associates with entity2_term (refs 1-3).
Raf-1
p21ras
1
These proteins, entity1_term (entity2_term) and 14-3-3 beta (HS1), are members of the 14-3-3 family of proteins.
14-3-3 zeta
PLA2
0
These proteins, entity1_term (PLA2) and entity2_term (HS1), are members of the 14-3-3 family of proteins.
14-3-3 zeta
14-3-3 beta
0
These proteins, entity1_term (PLA2) and 14-3-3 beta (entity2_term), are members of the 14-3-3 family of proteins.
14-3-3 zeta
HS1
0
These proteins, 14-3-3 zeta (entity1_term) and entity2_term (HS1), are members of the 14-3-3 family of proteins.
PLA2
14-3-3 beta
0
These proteins, 14-3-3 zeta (entity1_term) and 14-3-3 beta (entity2_term), are members of the 14-3-3 family of proteins.
PLA2
HS1
0
Expression of 14-3-3 proteins in Xenopus oocytes enhanced entity1_term activity and promoted entity2_term-dependent oocyte maturation.
Raf-1
Raf-1
0
These proteins, 14-3-3 zeta (PLA2) and entity1_term (entity2_term), are members of the 14-3-3 family of proteins.
14-3-3 beta
HS1
0
For the calibration, we used two sets of proteins, the entity1_term-Max-entity2_term helix-loop-helix proteins, and wild-type and dimerization-defective versions of the lambda cI repressor.
Myc
Mxi1
0
For the calibration, we used two sets of proteins, the entity1_term-entity2_term-Mxi1 helix-loop-helix proteins, and wild-type and dimerization-defective versions of the lambda cI repressor.
Myc
Max
0
For the calibration, we used two sets of proteins, the Myc-entity1_term-entity2_term helix-loop-helix proteins, and wild-type and dimerization-defective versions of the lambda cI repressor.
Max
Mxi1
0
The native and reconstituted entity1_term-entity2_term complexes have similar thermal stability and, like steroid receptor heterocomplexes, they are stabilized by molybdate.
pp60src
hsp90
1
As previously shown with reticulocyte lysate-reconstituted steroid receptor heteroprotein complexes, the reconstituted entity1_term multiprotein complex contains entity2_term, which is a major candidate for providing the protein unfoldase activity required for hsp90 association.
pp60src
hsp70
1
In addition, entity1_term in the lysate complexes with wild-type entity2_term, of which only a small portion is normally recovered in cytosol in the native multiprotein complex, and with the cellular homolog, pp60c-src, which has never been recovered in cytosol in the form of a native multiprotein complex with hsp90.
hsp90
pp60v-src
1
In addition, entity1_term in the lysate complexes with wild-type pp60v-src, of which only a small portion is normally recovered in cytosol in the native multiprotein complex, and with the cellular homolog, entity2_term, which has never been recovered in cytosol in the form of a native multiprotein complex with hsp90.
hsp90
pp60c-src
1
A rabbit reticulocyte lysate system that has been used to reconstitute functional complexes between steroid receptors and the 90-kDa heat shock protein (hsp90) has been used here to form complexes between the entity1_term tyrosine kinase and entity2_term.
pp60src
hsp90
1
Reticulocyte lysate forms complexes between entity1_term and a temperature-sensitive mutant of Rous sarcoma virus entity2_term, which is normally present in cytosol virtually entirely in the multiprotein complex form.
hsp90
pp60v-src
1
Reconstitution of the multiprotein complex of entity1_term, entity2_term, and p50 in a cell-free system.
pp60src
hsp90
1
Reconstitution of the multiprotein complex of entity1_term, hsp90, and entity2_term in a cell-free system.
pp60src
p50
0
Reconstitution of the multiprotein complex of pp60src, entity1_term, and entity2_term in a cell-free system.
hsp90
p50
0
A rabbit reticulocyte lysate system that has been used to reconstitute functional complexes between steroid receptors and the 90-kDa heat shock protein (entity1_term) has been used here to form complexes between the pp60src tyrosine kinase and entity2_term.
hsp90
hsp90
0
A rabbit reticulocyte lysate system that has been used to reconstitute functional complexes between steroid receptors and the 90-kDa heat shock protein (entity1_term) has been used here to form complexes between the entity2_term tyrosine kinase and hsp90.
hsp90
pp60src
0
In addition, hsp90 in the lysate complexes with wild-type entity1_term, of which only a small portion is normally recovered in cytosol in the native multiprotein complex, and with the cellular homolog, entity2_term, which has never been recovered in cytosol in the form of a native multiprotein complex with hsp90.
pp60v-src
pp60c-src
0
In addition, hsp90 in the lysate complexes with wild-type entity1_term, of which only a small portion is normally recovered in cytosol in the native multiprotein complex, and with the cellular homolog, pp60c-src, which has never been recovered in cytosol in the form of a native multiprotein complex with entity2_term.
pp60v-src
hsp90
0
In addition, hsp90 in the lysate complexes with wild-type pp60v-src, of which only a small portion is normally recovered in cytosol in the native multiprotein complex, and with the cellular homolog, entity1_term, which has never been recovered in cytosol in the form of a native multiprotein complex with entity2_term.
pp60c-src
hsp90
0
In addition, entity1_term in the lysate complexes with wild-type pp60v-src, of which only a small portion is normally recovered in cytosol in the native multiprotein complex, and with the cellular homolog, pp60c-src, which has never been recovered in cytosol in the form of a native multiprotein complex with entity2_term.
hsp90
hsp90
0
As previously shown with reticulocyte lysate-reconstituted steroid receptor heteroprotein complexes, the reconstituted entity1_term multiprotein complex contains hsp70, which is a major candidate for providing the protein unfoldase activity required for entity2_term association.
pp60src
hsp90
0
As previously shown with reticulocyte lysate-reconstituted steroid receptor heteroprotein complexes, the reconstituted pp60src multiprotein complex contains entity1_term, which is a major candidate for providing the protein unfoldase activity required for entity2_term association.
hsp70
hsp90
0
Here, we show that TRADD interacts strongly with entity1_term, another death domain protein that was shown previously to associate with entity2_term antigen.
RIP
Fas
1
The death domain of tumor necrosis factor (TNF) receptor-1 (entity1_term) triggers distinct signaling pathways leading to apoptosis and NF-kappa B activation through its interaction with the death domain protein entity2_term.
TNFR1
TRADD
1
Here, we show that entity1_term interacts strongly with entity2_term, another death domain protein that was shown previously to associate with Fas antigen.
TRADD
RIP
1
The death domain of entity1_term (TNFR1) triggers distinct signaling pathways leading to apoptosis and NF-kappa B activation through its interaction with the death domain protein entity2_term.
tumor necrosis factor (TNF) receptor-1
TRADD
1
TNF-dependent recruitment of the protein kinase entity1_term to the entity2_term signaling complex.
RIP
TNF receptor-1
0
The death domain of entity1_term (entity2_term) triggers distinct signaling pathways leading to apoptosis and NF-kappa B activation through its interaction with the death domain protein TRADD.
tumor necrosis factor (TNF) receptor-1
TNFR1
0
The death domain of entity1_term (TNFR1) triggers distinct signaling pathways leading to apoptosis and entity2_term activation through its interaction with the death domain protein TRADD.
tumor necrosis factor (TNF) receptor-1
NF-kappa B
0
The death domain of tumor necrosis factor (TNF) receptor-1 (TNFR1) triggers distinct signaling pathways leading to apoptosis and entity1_term activation through its interaction with the death domain protein entity2_term.
NF-kappa B
TRADD
0
Here, we show that entity1_term interacts strongly with RIP, another death domain protein that was shown previously to associate with entity2_term antigen.
TRADD
Fas
0
The death domain of tumor necrosis factor (TNF) receptor-1 (entity1_term) triggers distinct signaling pathways leading to apoptosis and entity2_term activation through its interaction with the death domain protein TRADD.
TNFR1
NF-kappa B
0
We also show that entity1_term is a serine-threonine kinase that is recruited by entity2_term to TNFR1 in a TNF-dependent process.
RIP
TRADD
0
We also show that entity1_term is a serine-threonine kinase that is recruited by TRADD to entity2_term in a TNF-dependent process.
RIP
TNFR1
0
We also show that RIP is a serine-threonine kinase that is recruited by entity1_term to entity2_term in a TNF-dependent process.
TRADD
TNFR1
0
Overexpression of the intact entity1_term protein induces both entity2_term activation and apoptosis.
RIP
NF-kappa B
0
However, expression of the death domain of entity1_term Induces apoptosis, but potently inhibits entity2_term activation by TNF.
RIP
NF-kappa B
0
These results suggest that distinct domains of entity1_term participate in the TNF signaling cascades leading to apoptosis and entity2_term activation.
RIP
NF-kappa B
0
Using the human RAD52 protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated entity1_term, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein entity2_term.
UBE2I
UBL1
1
The interaction of entity1_term with entity2_term is mediated by RAD52's self-association region.
UBE2I
RAD52
1
Using the human RAD52 protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated entity1_term, that interacts with RAD52, entity2_term, p53, and a ubiquitin-like protein UBL1.
UBE2I
RAD51
1
Using the human RAD52 protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated entity1_term, that interacts with RAD52, RAD51, entity2_term, and a ubiquitin-like protein UBL1.
UBE2I
p53
1
Associations of entity1_term with RAD52, UBL1, p53, and entity2_term proteins in a yeast two-hybrid system.
UBE2I
RAD51
1
Using the human RAD52 protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated entity1_term, that interacts with entity2_term, RAD51, p53, and a ubiquitin-like protein UBL1.
UBE2I
RAD52
1
Associations of entity1_term with RAD52, entity2_term, p53, and RAD51 proteins in a yeast two-hybrid system.
UBE2I
UBL1
1
Associations of entity1_term with RAD52, UBL1, entity2_term, and RAD51 proteins in a yeast two-hybrid system.
UBE2I
p53
1
Associations of entity1_term with entity2_term, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.
UBE2I
RAD52
1
Associations of UBE2I with entity1_term, entity2_term, p53, and RAD51 proteins in a yeast two-hybrid system.
RAD52
UBL1
0
Associations of UBE2I with RAD52, entity1_term, entity2_term, and RAD51 proteins in a yeast two-hybrid system.
UBL1
p53
0
Associations of UBE2I with RAD52, entity1_term, p53, and entity2_term proteins in a yeast two-hybrid system.
UBL1
RAD51
0
Associations of UBE2I with entity1_term, UBL1, entity2_term, and RAD51 proteins in a yeast two-hybrid system.
RAD52
p53
0
Associations of UBE2I with entity1_term, UBL1, p53, and entity2_term proteins in a yeast two-hybrid system.
RAD52
RAD51
0
Associations of UBE2I with RAD52, UBL1, entity1_term, and entity2_term proteins in a yeast two-hybrid system.
p53
RAD51
0
Using the human entity1_term protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated entity2_term, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.
RAD52
UBE2I
0
Using the human RAD52 protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast entity1_term, designated entity2_term, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.
UBC9
UBE2I
0
Using the human RAD52 protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with entity1_term, entity2_term, p53, and a ubiquitin-like protein UBL1.
RAD52
RAD51
0
Using the human entity1_term protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with entity2_term, RAD51, p53, and a ubiquitin-like protein UBL1.
RAD52
RAD52
0
Using the human RAD52 protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with entity1_term, RAD51, entity2_term, and a ubiquitin-like protein UBL1.
RAD52
p53
0
Using the human RAD52 protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with entity1_term, RAD51, p53, and a ubiquitin-like protein entity2_term.
RAD52
UBL1
0
Using the human RAD52 protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast entity1_term, designated UBE2I, that interacts with entity2_term, RAD51, p53, and a ubiquitin-like protein UBL1.
UBC9
RAD52
0
Using the human entity1_term protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, entity2_term, p53, and a ubiquitin-like protein UBL1.
RAD52
RAD51
0
Using the human RAD52 protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, entity1_term, entity2_term, and a ubiquitin-like protein UBL1.
RAD51
p53
0
Using the human RAD52 protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, entity1_term, p53, and a ubiquitin-like protein entity2_term.
RAD51
UBL1
0
Using the human RAD52 protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast entity1_term, designated UBE2I, that interacts with RAD52, entity2_term, p53, and a ubiquitin-like protein UBL1.
UBC9
RAD51
0
Using the human entity1_term protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, entity2_term, and a ubiquitin-like protein UBL1.
RAD52
p53
0
Using the human entity1_term protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein entity2_term.
RAD52
UBL1
0
Using the human entity1_term protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast entity2_term, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.
RAD52
UBC9
0
Using the human RAD52 protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, entity1_term, and a ubiquitin-like protein entity2_term.
p53
UBL1
0
Using the human RAD52 protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast entity1_term, designated UBE2I, that interacts with RAD52, RAD51, entity2_term, and a ubiquitin-like protein UBL1.
UBC9
p53
0
Using the human RAD52 protein as the "bait" in a yeast two-hybrid system, we have identified a human homolog of yeast entity1_term, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein entity2_term.
UBC9
UBL1
0
These interactions are entity1_term-specific, since another DNA repair-related ubiquitin-conjugating enzyme, entity2_term (UBC2), does not interact with these proteins.
UBE2I
RAD6
0
These interactions are entity1_term-specific, since another DNA repair-related ubiquitin-conjugating enzyme, RAD6 (entity2_term), does not interact with these proteins.
UBE2I
UBC2
0
These interactions are UBE2I-specific, since another DNA repair-related ubiquitin-conjugating enzyme, entity1_term (entity2_term), does not interact with these proteins.
RAD6
UBC2
0
These results suggest that the RAD52-dependent processes, cell cycle control, entity1_term-mediated pathway(s), and ubiquitination interact through human entity2_term.
p53
UBE2I
0
These results suggest that the entity1_term-dependent processes, cell cycle control, p53-mediated pathway(s), and ubiquitination interact through human entity2_term.
RAD52
UBE2I
0
These results suggest that the entity1_term-dependent processes, cell cycle control, entity2_term-mediated pathway(s), and ubiquitination interact through human UBE2I.
RAD52
p53
0
The interaction of entity1_term with RAD52 is mediated by entity2_term's self-association region.
UBE2I
RAD52
0
The interaction of UBE2I with entity1_term is mediated by entity2_term's self-association region.
RAD52
RAD52
0
We demonstrate that entity1_term forms a specific complex with the cytoplasmic domain of the entity2_term when both are expressed as hybrid proteins in yeast cells.
IRS-1
insulin receptor
1
Although entity1_term is thought to interact with the entity2_term, the nature of the interaction has not been defined.
IRS-1
insulin receptor
1
In this study, we used the two-hybrid assay of protein-protein interaction in the yeast Saccharomyces cerevisiae to study the interaction between human entity1_term and the entity2_term.
IRS-1
insulin receptor
1
entity1_term (IRS-1) is a major substrate of the entity2_term and has been implicated in insulin signaling.
Insulin receptor substrate 1
insulin receptor
1
Insulin receptor substrate 1 (entity1_term) is a major substrate of the entity2_term and has been implicated in insulin signaling.
IRS-1
insulin receptor
1
Characterization of an interaction between entity1_term and the entity2_term by using the two-hybrid system.
insulin receptor substrate 1
insulin receptor
1
entity1_term (IRS-1) is a major substrate of the insulin receptor and has been implicated in entity2_term signaling.
Insulin receptor substrate 1
insulin
0
entity1_term (entity2_term) is a major substrate of the insulin receptor and has been implicated in insulin signaling.
Insulin receptor substrate 1
IRS-1
0
Insulin receptor substrate 1 (entity1_term) is a major substrate of the insulin receptor and has been implicated in entity2_term signaling.
IRS-1
insulin
0
Insulin receptor substrate 1 (IRS-1) is a major substrate of the entity1_term and has been implicated in entity2_term signaling.
insulin receptor
insulin
0
Although entity1_term is thought to interact with the entity2_term receptor, the nature of the interaction has not been defined.
IRS-1
insulin
0
In this study, we used the two-hybrid assay of protein-protein interaction in the yeast Saccharomyces cerevisiae to study the interaction between human entity1_term and the entity2_term receptor.
IRS-1
insulin
0
In this study, we used the two-hybrid assay of protein-protein interaction in the yeast Saccharomyces cerevisiae to study the interaction between human IRS-1 and the entity1_termentity2_term.
insulin
insulin receptor
0
Although IRS-1 is thought to interact with the entity1_termentity2_term, the nature of the interaction has not been defined.
insulin
insulin receptor
0
Lastly, in agreement with our findings for yeast cells, we show that the entity1_term is unable to phosphorylate an entity2_term protein containing a deletion of amino acids 45 to 516 when expressed in COS cells.
insulin receptor
IRS-1
0
Using a genetic selection based on protein-protein interaction in yeast, we have identified two gene products that associate with the intracellular domain of entity1_term: Fas itself, and a novel 74 kDa protein we have named RIP, for entity2_term.
Fas
receptor interacting protein
1
entity1_term also interacts weakly with the p55 tumor necrosis factor receptor (entity2_term) intracellular domain, but not with a mutant version of Fas corresponding to the murine lprcg mutation.
RIP
TNFR1
1
Using a genetic selection based on protein-protein interaction in yeast, we have identified two gene products that associate with the intracellular domain of entity1_term: entity2_term itself, and a novel 74 kDa protein we have named RIP, for receptor interacting protein.
Fas
Fas
1
Using a genetic selection based on protein-protein interaction in yeast, we have identified two gene products that associate with the intracellular domain of entity1_term: Fas itself, and a novel 74 kDa protein we have named entity2_term, for receptor interacting protein.
Fas
RIP
1
entity1_term: a novel protein containing a death domain that interacts with Fas/entity2_term (CD95) in yeast and causes cell death.
RIP
APO-1
1
entity1_term: a novel protein containing a death domain that interacts with Fas/APO-1 (entity2_term) in yeast and causes cell death.
RIP
CD95
1
entity1_term: a novel protein containing a death domain that interacts with entity2_term/APO-1 (CD95) in yeast and causes cell death.
RIP
Fas
1
RIP: a novel protein containing a death domain that interacts with entity1_term/entity2_term (CD95) in yeast and causes cell death.
Fas
APO-1
0
RIP: a novel protein containing a death domain that interacts with Fas/entity1_term (entity2_term) in yeast and causes cell death.
APO-1
CD95
0
RIP: a novel protein containing a death domain that interacts with entity1_term/APO-1 (entity2_term) in yeast and causes cell death.
Fas
CD95
0
Ligation of the extracellular domain of the cell surface receptor Fas/entity1_term (entity2_term) elicits a characteristic programmed death response in susceptible cells.
APO-1
CD95
0
Ligation of the extracellular domain of the cell surface receptor entity1_term/entity2_term (CD95) elicits a characteristic programmed death response in susceptible cells.
Fas
APO-1
0
Ligation of the extracellular domain of the cell surface receptor entity1_term/APO-1 (entity2_term) elicits a characteristic programmed death response in susceptible cells.
Fas
CD95
0
Using a genetic selection based on protein-protein interaction in yeast, we have identified two gene products that associate with the intracellular domain of Fas: Fas itself, and a novel 74 kDa protein we have named entity1_term, for entity2_term.
RIP
receptor interacting protein
0
Using a genetic selection based on protein-protein interaction in yeast, we have identified two gene products that associate with the intracellular domain of Fas: entity1_term itself, and a novel 74 kDa protein we have named entity2_term, for receptor interacting protein.
Fas
RIP
0
Using a genetic selection based on protein-protein interaction in yeast, we have identified two gene products that associate with the intracellular domain of Fas: entity1_term itself, and a novel 74 kDa protein we have named RIP, for entity2_term.
Fas
receptor interacting protein
0
entity1_term also interacts weakly with the entity2_term tumor necrosis factor receptor (TNFR1) intracellular domain, but not with a mutant version of Fas corresponding to the murine lprcg mutation.
RIP
p55
0
entity1_term also interacts weakly with the p55 tumor necrosis factor receptor (TNFR1) intracellular domain, but not with a mutant version of entity2_term corresponding to the murine lprcg mutation.
RIP
Fas
0
RIP also interacts weakly with the entity1_term tumor necrosis factor receptor (entity2_term) intracellular domain, but not with a mutant version of Fas corresponding to the murine lprcg mutation.
p55
TNFR1
0
RIP also interacts weakly with the entity1_term tumor necrosis factor receptor (TNFR1) intracellular domain, but not with a mutant version of entity2_term corresponding to the murine lprcg mutation.
p55
Fas
0
RIP also interacts weakly with the p55 tumor necrosis factor receptor (entity1_term) intracellular domain, but not with a mutant version of entity2_term corresponding to the murine lprcg mutation.
TNFR1
Fas
0
entity1_term contains an N-terminal region with homology to protein kinases and a C-terminal region containing a cytoplasmic motif (death domain) present in the entity2_term and TNFR1 intracellular domains.
RIP
Fas
0
entity1_term contains an N-terminal region with homology to protein kinases and a C-terminal region containing a cytoplasmic motif (death domain) present in the Fas and entity2_term intracellular domains.
RIP
TNFR1
0
RIP contains an N-terminal region with homology to protein kinases and a C-terminal region containing a cytoplasmic motif (death domain) present in the entity1_term and entity2_term intracellular domains.
Fas
TNFR1
0
Interestingly, the entity1_term binding site overlaps the largest continuous hydrophobic patch on entity2_term.
ifnar2
IFNalpha2
1
Here, we quantitatively mapped the complete binding region of entity1_term on entity2_term by 35 individual mutations to alanine and isosteric residues.
ifnar2
interferon (IFN)alpha2
1
Relating the anti-viral and anti-proliferative activity of the various interferon mutants with their affinity toward entity1_term results in linear function over the whole range of affinities investigated, suggesting that entity2_term binding is the rate-determining step in cellular activation.
ifnar2
ifnar2
0
Type I interferons bind to two cell surface receptors, entity1_term and entity2_term, as the first step in the activation of several signal transduction pathways that elicit an anti-viral state and an anti-proliferative response.
ifnar1
ifnar2
0
We previously have shown that entity1_term purified from human HeLa cells is a multisubunit complex of four polypeptides designated entity2_term, -beta, -gamma, and -delta.
PTF
PTF alpha
0
We previously have shown that PTF purified from human HeLa cells is a multisubunit complex of four polypeptides designated entity1_termentity2_term alpha, -beta, -gamma, and -delta.
PTF alpha
PTF
0
We now report the isolation and expression of cDNAs encoding entity1_term gamma and entity2_term delta, as well as functional studies with cognate antibodies that recognize the native PTF complex in HeLa extracts.
PTF
PTF
0
We now report the isolation and expression of cDNAs encoding entity1_term gamma and PTF delta, as well as functional studies with cognate antibodies that recognize the native entity2_term complex in HeLa extracts.
PTF
PTF
0
We previously have shown that entity1_term purified from human HeLa cells is a multisubunit complex of four polypeptides designated entity2_term alpha, -beta, -gamma, and -delta.
PTF
PTF
0
In addition, we show that in extracts depleted of entity1_term and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a entity2_term complex different from the one used for mRNA-encoding genes.
TBP
TBP
0
In addition, we show that in extracts depleted of entity1_term and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or entity2_term, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.
TBP
TFIIIB
0
In addition, we show that in extracts depleted of entity1_term and entity2_term-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.
TBP
TBP
0
In addition, we show that in extracts depleted of entity1_term and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by entity2_term or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.
TBP
TFIID
0
In addition, we show that in extracts depleted of entity1_term and TBP-associated factors, transcription from the U1 promoter is restored by recombinant entity2_term but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.
TBP
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound entity1_term and TATA-bound entity2_term during promoter activation.
PTF
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-entity1_term-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound entity2_term during promoter activation.
TBP
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable entity1_term-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound entity2_term during promoter activation.
TBP
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with entity1_term in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound entity2_term during promoter activation.
PTF
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of entity1_term with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound entity2_term during promoter activation.
TBP
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with entity1_term, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound entity2_term during promoter activation.
TBP
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and entity1_term delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound entity2_term during promoter activation.
PTF
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant entity1_term gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound entity2_term during promoter activation.
PTF
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-entity1_term-associated factor complex or with possible functional interactions between PSE-bound entity2_term and TATA-bound TBP during promoter activation.
TBP
PTF
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable entity1_term-TBP-associated factor complex or with possible functional interactions between PSE-bound entity2_term and TATA-bound TBP during promoter activation.
TBP
PTF
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with entity1_term in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound entity2_term and TATA-bound TBP during promoter activation.
PTF
PTF
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of entity1_term with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound entity2_term and TATA-bound TBP during promoter activation.
TBP
PTF
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with entity1_term, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound entity2_term and TATA-bound TBP during promoter activation.
TBP
PTF
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and entity1_term delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound entity2_term and TATA-bound TBP during promoter activation.
PTF
PTF
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant entity1_term gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound entity2_term and TATA-bound TBP during promoter activation.
PTF
PTF
0
We now report the isolation and expression of cDNAs encoding PTF gamma and entity1_term delta, as well as functional studies with cognate antibodies that recognize the native entity2_term complex in HeLa extracts.
PTF
PTF
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable entity1_term-entity2_term-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.
TBP
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with entity1_term in a semistable TBP-entity2_term-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.
PTF
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of entity1_term with PTF in a semistable TBP-entity2_term-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.
TBP
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with entity1_term, consistent either with the natural association of TBP with PTF in a semistable TBP-entity2_term-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.
TBP
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and entity1_term delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-entity2_term-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.
PTF
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant entity1_term gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-entity2_term-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.
PTF
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of TBP with entity1_term in a semistable entity2_term-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.
PTF
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of entity1_term with PTF in a semistable entity2_term-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.
TBP
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with entity1_term, consistent either with the natural association of TBP with PTF in a semistable entity2_term-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.
TBP
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and entity1_term delta with TBP, consistent either with the natural association of TBP with PTF in a semistable entity2_term-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.
PTF
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant entity1_term gamma and PTF delta with TBP, consistent either with the natural association of TBP with PTF in a semistable entity2_term-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.
PTF
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP, consistent either with the natural association of entity1_term with entity2_term in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.
TBP
PTF
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with entity1_term, consistent either with the natural association of TBP with entity2_term in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.
TBP
PTF
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and entity1_term delta with TBP, consistent either with the natural association of TBP with entity2_term in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.
PTF
PTF
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant entity1_term gamma and PTF delta with TBP, consistent either with the natural association of TBP with entity2_term in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.
PTF
PTF
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with entity1_term, consistent either with the natural association of entity2_term with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.
TBP
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and entity1_term delta with TBP, consistent either with the natural association of entity2_term with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.
PTF
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant entity1_term gamma and PTF delta with TBP, consistent either with the natural association of entity2_term with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.
PTF
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and entity1_term delta with entity2_term, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.
PTF
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant entity1_term gamma and PTF delta with entity2_term, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.
PTF
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant entity1_term gamma and entity2_term delta with TBP, consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation.
PTF
PTF
0
The entity1_term (entity2_term) specifically recognizes the PSEs of both RNA polymerase II- and RNA polymerase III-transcribed small nuclear RNA (snRNA) genes.
proximal sequence element (PSE)-binding transcription factor
PTF
0
Immunoprecipitation studies confirm that the four entity1_term subunits originally found to copurify during conventional chromatography indeed form a tightly associated complex; they further show that the entity2_term so defined, including the gamma and delta subunits specifically, is essential for transcription of both class II and class III snRNA genes.
PTF
PTF
0
Immunoprecipitation assays also show a weak substoichiometric association of the entity1_term (entity2_term) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.
TATA-binding protein
TBP
0
Immunoprecipitation assays also show a weak substoichiometric association of the entity1_term (TBP) with entity2_term, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.
TATA-binding protein
PTF
0
Immunoprecipitation assays also show a weak substoichiometric association of the entity1_term (TBP) with PTF, consistent with the previous report of a entity2_term-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.
TATA-binding protein
PTF
0
Immunoprecipitation assays also show a weak substoichiometric association of the entity1_term (TBP) with PTF, consistent with the previous report of a PTF-related complex (entity2_term) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.
TATA-binding protein
SNAPc
0
Immunoprecipitation assays also show a weak substoichiometric association of the entity1_term (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of entity2_term and a component (SNAPc43) identical in sequence to the PTF gamma reported here.
TATA-binding protein
TBP
0
Immunoprecipitation assays also show a weak substoichiometric association of the entity1_term (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (entity2_term) identical in sequence to the PTF gamma reported here.
TATA-binding protein
SNAPc43
0
Immunoprecipitation assays also show a weak substoichiometric association of the entity1_term (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the entity2_term gamma reported here.
TATA-binding protein
PTF
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (entity1_term) with entity2_term, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.
TBP
PTF
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (entity1_term) with PTF, consistent with the previous report of a entity2_term-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.
TBP
PTF
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (entity1_term) with PTF, consistent with the previous report of a PTF-related complex (entity2_term) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.
TBP
SNAPc
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (entity1_term) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of entity2_term and a component (SNAPc43) identical in sequence to the PTF gamma reported here.
TBP
TBP
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (entity1_term) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (entity2_term) identical in sequence to the PTF gamma reported here.
TBP
SNAPc43
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (entity1_term) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the entity2_term gamma reported here.
TBP
PTF
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with entity1_term, consistent with the previous report of a entity2_term-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.
PTF
PTF
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with entity1_term, consistent with the previous report of a PTF-related complex (entity2_term) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.
PTF
SNAPc
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with entity1_term, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of entity2_term and a component (SNAPc43) identical in sequence to the PTF gamma reported here.
PTF
TBP
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with entity1_term, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (entity2_term) identical in sequence to the PTF gamma reported here.
PTF
SNAPc43
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with entity1_term, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the entity2_term gamma reported here.
PTF
PTF
0
In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or entity1_term, indicating that transcription of class II snRNA genes requires a entity2_term complex different from the one used for mRNA-encoding genes.
TFIIIB
TBP
0
In addition, we show that in extracts depleted of TBP and entity1_term-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a entity2_term complex different from the one used for mRNA-encoding genes.
TBP
TBP
0
In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by entity1_term or TFIIIB, indicating that transcription of class II snRNA genes requires a entity2_term complex different from the one used for mRNA-encoding genes.
TFIID
TBP
0
In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant entity1_term but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a entity2_term complex different from the one used for mRNA-encoding genes.
TBP
TBP
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a entity1_term-related complex (entity2_term) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the PTF gamma reported here.
PTF
SNAPc
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a entity1_term-related complex (SNAPc) containing substoichiometric levels of entity2_term and a component (SNAPc43) identical in sequence to the PTF gamma reported here.
PTF
TBP
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a entity1_term-related complex (SNAPc) containing substoichiometric levels of TBP and a component (entity2_term) identical in sequence to the PTF gamma reported here.
PTF
SNAPc43
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a entity1_term-related complex (SNAPc) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the entity2_term gamma reported here.
PTF
PTF
0
In addition, we show that in extracts depleted of TBP and entity1_term-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or entity2_term, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.
TBP
TFIIIB
0
In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by entity1_term or entity2_term, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.
TFIID
TFIIIB
0
In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant entity1_term but not by TFIID or entity2_term, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.
TBP
TFIIIB
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (entity1_term) containing substoichiometric levels of entity2_term and a component (SNAPc43) identical in sequence to the PTF gamma reported here.
SNAPc
TBP
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (entity1_term) containing substoichiometric levels of TBP and a component (entity2_term) identical in sequence to the PTF gamma reported here.
SNAPc
SNAPc43
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (entity1_term) containing substoichiometric levels of TBP and a component (SNAPc43) identical in sequence to the entity2_term gamma reported here.
SNAPc
PTF
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of entity1_term and a component (entity2_term) identical in sequence to the PTF gamma reported here.
TBP
SNAPc43
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of entity1_term and a component (SNAPc43) identical in sequence to the entity2_term gamma reported here.
TBP
PTF
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein (TBP) with PTF, consistent with the previous report of a PTF-related complex (SNAPc) containing substoichiometric levels of TBP and a component (entity1_term) identical in sequence to the entity2_term gamma reported here.
SNAPc43
PTF
0
In addition, we show that in extracts depleted of TBP and entity1_term-associated factors, transcription from the U1 promoter is restored by recombinant TBP but not by entity2_term or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.
TBP
TFIID
0
In addition, we show that in extracts depleted of TBP and entity1_term-associated factors, transcription from the U1 promoter is restored by recombinant entity2_term but not by TFIID or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.
TBP
TBP
0
In addition, we show that in extracts depleted of TBP and TBP-associated factors, transcription from the U1 promoter is restored by recombinant entity1_term but not by entity2_term or TFIIIB, indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes.
TBP
TFIID
0
Present data concerning the entity1_term-entity2_term system of extrarenal origin.
renin
angiotensin
0
After a brief historical incursion regarding entity1_term of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, entity2_term, D and G cathepsin and ending with the conversion enzyme and chymase.
RAS
tonin
0
After a brief historical incursion regarding entity1_term of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and entity2_term and ending with the conversion enzyme and chymase.
RAS
G cathepsin
0
After a brief historical incursion regarding entity1_term of renal origin, we present the main extrarenal entity2_term-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.
RAS
angiotensin
0
After a brief historical incursion regarding entity1_term of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with entity2_term, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.
RAS
isorenin
0
After a brief historical incursion regarding entity1_term of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and entity2_term.
RAS
chymase
0
After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, entity1_term, D and entity2_term and ending with the conversion enzyme and chymase.
tonin
G cathepsin
0
After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal entity1_term-forming enzymes, starting with isorenin, entity2_term, D and G cathepsin and ending with the conversion enzyme and chymase.
angiotensin
tonin
0
After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with entity1_term, entity2_term, D and G cathepsin and ending with the conversion enzyme and chymase.
isorenin
tonin
0
After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, entity1_term, D and G cathepsin and ending with the conversion enzyme and entity2_term.
tonin
chymase
0
After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal entity1_term-forming enzymes, starting with isorenin, tonin, D and entity2_term and ending with the conversion enzyme and chymase.
angiotensin
G cathepsin
0
After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with entity1_term, tonin, D and entity2_term and ending with the conversion enzyme and chymase.
isorenin
G cathepsin
0
After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with isorenin, tonin, D and entity1_term and ending with the conversion enzyme and entity2_term.
G cathepsin
chymase
0
After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal entity1_term-forming enzymes, starting with entity2_term, tonin, D and G cathepsin and ending with the conversion enzyme and chymase.
angiotensin
isorenin
0
After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal entity1_term-forming enzymes, starting with isorenin, tonin, D and G cathepsin and ending with the conversion enzyme and entity2_term.
angiotensin
chymase
0
After a brief historical incursion regarding RAS of renal origin, we present the main extrarenal angiotensin-forming enzymes, starting with entity1_term, tonin, D and G cathepsin and ending with the conversion enzyme and entity2_term.
isorenin
chymase
0
In the end we refer to the relations between circulating entity1_term of renal origin and the extrarenal entity2_term specific to tissue underlying the fact that the two RAS components cooperate and constitute a unitary hormonal system, regulating the major functions of the organism and maintaining the main homeostatic equilibria.
RAS
RAS
0
In the end we refer to the relations between circulating entity1_term of renal origin and the extrarenal RAS specific to tissue underlying the fact that the two entity2_term components cooperate and constitute a unitary hormonal system, regulating the major functions of the organism and maintaining the main homeostatic equilibria.
RAS
RAS
0
In the end we refer to the relations between circulating RAS of renal origin and the extrarenal entity1_term specific to tissue underlying the fact that the two entity2_term components cooperate and constitute a unitary hormonal system, regulating the major functions of the organism and maintaining the main homeostatic equilibria.
RAS
RAS
0
While the circulating entity1_term of renal origin is acutely activated to contribute to the accomplishment of short term homeostatic reactions, tissue entity2_term, in paracrine or autocrine ways, exerts local-regional adaptive actions of long duration.
RAS
RAS
0
entity1_term (neuromodulin, B-50, F1), a entity2_term (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.
GAP-43
protein kinase C
1
Surprisingly, the N-terminal third of GAP-43 alone bound entity1_term more strongly than did intact entity2_term, suggesting that the protein's C-terminus may play a role in modulating the interaction with CaM.
CaM
GAP-43
1
These results, along with other recent findings, suggest a novel role for the interaction between entity1_term and entity2_term.
GAP-43
CaM
1
entity1_term phosphorylates entity2_term on serine 41.
PKC
GAP-43
1
Surprisingly, the N-terminal third of entity1_term alone bound entity2_term more strongly than did intact GAP-43, suggesting that the protein's C-terminus may play a role in modulating the interaction with CaM.
GAP-43
CaM
1
In the yeast-based cloning system, the only strong interaction that was detected between entity1_term and the calcium effector protein, calmodulin (entity2_term).
GAP-43
CaM
1
GAP-43 (neuromodulin, B-50, entity1_term), a protein kinase C (entity2_term) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.
F1
PKC
1
In the yeast-based cloning system, the only strong interaction that was detected between entity1_term and the calcium effector protein, entity2_term (CaM).
GAP-43
calmodulin
1
GAP-43 (neuromodulin, entity1_term, F1), a protein kinase C (entity2_term) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.
B-50
PKC
1
GAP-43 (neuromodulin, B-50, entity1_term), a entity2_term (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.
F1
protein kinase C
1
GAP-43 (entity1_term, B-50, F1), a protein kinase C (entity2_term) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.
neuromodulin
PKC
1
GAP-43 (neuromodulin, entity1_term, F1), a entity2_term (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.
B-50
protein kinase C
1
entity1_term (neuromodulin, B-50, F1), a protein kinase C (entity2_term) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.
GAP-43
PKC
1
GAP-43 (entity1_term, B-50, F1), a entity2_term (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.
neuromodulin
protein kinase C
1
entity1_term (neuromodulin, B-50, entity2_term), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.
GAP-43
F1
0
entity1_term (entity2_term, B-50, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.
GAP-43
neuromodulin
0
entity1_term (neuromodulin, entity2_term, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.
GAP-43
B-50
0
GAP-43 (entity1_term, B-50, entity2_term), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.
neuromodulin
F1
0
GAP-43 (neuromodulin, entity1_term, entity2_term), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.
B-50
F1
0
GAP-43 (neuromodulin, B-50, F1), a entity1_term (entity2_term) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.
protein kinase C
PKC
0
GAP-43 (entity1_term, entity2_term, F1), a protein kinase C (PKC) substrate important for the growth and plasticity of neuronal connections, has been implicated in vitro in several signal transduction pathways.
neuromodulin
B-50
0
In the yeast-based cloning system, the only strong interaction that was detected between GAP-43 and the entity1_term, entity2_term (CaM).
calcium effector protein
calmodulin
0
In the yeast-based cloning system, the only strong interaction that was detected between GAP-43 and the entity1_term, calmodulin (entity2_term).
calcium effector protein
CaM
0
In the yeast-based cloning system, the only strong interaction that was detected between entity1_term and the entity2_term, calmodulin (CaM).
GAP-43
calcium effector protein
0
In the yeast-based cloning system, the only strong interaction that was detected between GAP-43 and the calcium effector protein, entity1_term (entity2_term).
calmodulin
CaM
0
Surprisingly, the N-terminal third of entity1_term alone bound CaM more strongly than did intact entity2_term, suggesting that the protein's C-terminus may play a role in modulating the interaction with CaM.
GAP-43
GAP-43
0
Surprisingly, the N-terminal third of entity1_term alone bound CaM more strongly than did intact GAP-43, suggesting that the protein's C-terminus may play a role in modulating the interaction with entity2_term.
GAP-43
CaM
0
Surprisingly, the N-terminal third of GAP-43 alone bound entity1_term more strongly than did intact GAP-43, suggesting that the protein's C-terminus may play a role in modulating the interaction with entity2_term.
CaM
CaM
0
Surprisingly, the N-terminal third of GAP-43 alone bound CaM more strongly than did intact entity1_term, suggesting that the protein's C-terminus may play a role in modulating the interaction with entity2_term.
GAP-43
CaM
0
The specificity of intehraction between entity1_term and entity2_term was confirmed by an in vitro binding assay using recombinant proteins.
G alpha i2
nucleobindin
1
Interaction of the protein entity1_term with entity2_term, as revealed by the yeast two-hybrid system.
nucleobindin
G alpha i2
1
Transfection of entity1_term and entity2_term in COS cells increased G alpha i2 expression relative to cells transfected with G alpha i2 and mock vector.
G alpha i2
nucleobindin
0
Transfection of entity1_term and nucleobindin in COS cells increased entity2_term expression relative to cells transfected with G alpha i2 and mock vector.
G alpha i2
G alpha i2
0
Transfection of entity1_term and nucleobindin in COS cells increased G alpha i2 expression relative to cells transfected with entity2_term and mock vector.
G alpha i2
G alpha i2
0
Transfection of G alpha i2 and entity1_term in COS cells increased entity2_term expression relative to cells transfected with G alpha i2 and mock vector.
nucleobindin
G alpha i2
0
Transfection of G alpha i2 and entity1_term in COS cells increased G alpha i2 expression relative to cells transfected with entity2_term and mock vector.
nucleobindin
G alpha i2
0
Transfection of G alpha i2 and nucleobindin in COS cells increased entity1_term expression relative to cells transfected with entity2_term and mock vector.
G alpha i2
G alpha i2
0
The results show that entity1_term heterodimerizes with E12 and entity2_term in vivo, but it does not homodimerize to a measurable extent.
myogenin
E47
1
entity1_term is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins, such as the E2A gene products E12 and entity2_term.
Myogenin
E47
1
The results show that entity1_term heterodimerizes with entity2_term and E47 in vivo, but it does not homodimerize to a measurable extent.
myogenin
E12
1
entity1_term is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins, such as the E2A gene products entity2_term and E47.
Myogenin
E12
1
Analysis of the oligomerization of entity1_term and entity2_term products in vivo using a two-hybrid assay system.
myogenin
E2A
0
entity1_term is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins, such as the entity2_term gene products E12 and E47.
Myogenin
E2A
0
Myogenin is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins, such as the entity1_term gene products E12 and entity2_term.
E2A
E47
0
Myogenin is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins, such as the E2A gene products entity1_term and entity2_term.
E12
E47
0
Myogenin is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins, such as the entity1_term gene products entity2_term and E47.
E2A
E12
0
The results show that myogenin heterodimerizes with entity1_term and entity2_term in vivo, but it does not homodimerize to a measurable extent.
E12
E47
0
Peptide growth factors, as well as the immediate early gene products entity1_term, entity2_term, and c-Myc, inhibit the activity of myogenin through a mechanism independent of its association with E2A products.
c-Jun
v-Fos
0
Peptide growth factors, as well as the immediate early gene products entity1_term, v-Fos, and entity2_term, inhibit the activity of myogenin through a mechanism independent of its association with E2A products.
c-Jun
c-Myc
0
Peptide growth factors, as well as the immediate early gene products entity1_term, v-Fos, and c-Myc, inhibit the activity of myogenin through a mechanism independent of its association with entity2_term products.
c-Jun
E2A
0
Peptide growth factors, as well as the immediate early gene products c-Jun, entity1_term, and entity2_term, inhibit the activity of myogenin through a mechanism independent of its association with E2A products.
v-Fos
c-Myc
0
Peptide growth factors, as well as the immediate early gene products c-Jun, entity1_term, and c-Myc, inhibit the activity of myogenin through a mechanism independent of its association with entity2_term products.
v-Fos
E2A
0
Peptide growth factors, as well as the immediate early gene products c-Jun, v-Fos, and entity1_term, inhibit the activity of myogenin through a mechanism independent of its association with entity2_term products.
c-Myc
E2A
0
When human embryonic kidney cells (cell line 293) over-expressing IL-1RI or HeLa cells were exposed to IL-1, entity1_term rapidly associated with the entity2_term complex and was phosphorylated.
IRAK
IL-1RI
1
The pleiotropic biological activities of entity1_term (IL-1) are mediated by its type I receptor (entity2_term).
interleukin-1
IL-1RI
1
The pleiotropic biological activities of interleukin-1 (entity1_term) are mediated by its type I receptor (entity2_term).
IL-1
IL-1RI
1
entity1_term: a kinase associated with the entity2_term.
IRAK
interleukin-1 receptor
1
The pleiotropic biological activities of entity1_term (entity2_term) are mediated by its type I receptor (IL-1RI).
interleukin-1
IL-1
0
When the ligand binds, entity1_term initiates a signaling cascade that results in the activation of the transcription regulator entity2_term (NF-kappa B).
IL-1RI
nuclear factor kappa B
0
When the ligand binds, entity1_term initiates a signaling cascade that results in the activation of the transcription regulator nuclear factor kappa B (entity2_term).
IL-1RI
NF-kappa B
0
When the ligand binds, IL-1RI initiates a signaling cascade that results in the activation of the transcription regulator entity1_term (entity2_term).
nuclear factor kappa B
NF-kappa B
0
A protein kinase designated IRAK (entity1_termentity2_term) was purified, and its complementary DNA was molecularly cloned.
IL-1
IL-1 receptor-associated kinase
0
A protein kinase designated entity1_term (entity2_term receptor-associated kinase) was purified, and its complementary DNA was molecularly cloned.
IRAK
IL-1
0
A protein kinase designated entity1_term (entity2_term) was purified, and its complementary DNA was molecularly cloned.
IRAK
IL-1 receptor-associated kinase
0
When human embryonic kidney cells (cell line 293) over-expressing entity1_term or HeLa cells were exposed to entity2_term, IRAK rapidly associated with the IL-1RI complex and was phosphorylated.
IL-1RI
IL-1
0
When human embryonic kidney cells (cell line 293) over-expressing entity1_term or HeLa cells were exposed to IL-1, entity2_term rapidly associated with the IL-1RI complex and was phosphorylated.
IL-1RI
IRAK
0
When human embryonic kidney cells (cell line 293) over-expressing entity1_term or HeLa cells were exposed to IL-1, IRAK rapidly associated with the entity2_term complex and was phosphorylated.
IL-1RI
IL-1RI
0
When human embryonic kidney cells (cell line 293) over-expressing IL-1RI or HeLa cells were exposed to entity1_term, entity2_term rapidly associated with the IL-1RI complex and was phosphorylated.
IL-1
IRAK
0
When human embryonic kidney cells (cell line 293) over-expressing IL-1RI or HeLa cells were exposed to entity1_term, IRAK rapidly associated with the entity2_term complex and was phosphorylated.
IL-1
IL-1RI
0
The primary amino acid sequence of entity1_term shares similarity with that of pelle,a protein kinase that is essential for the activation of a entity2_term homolog in Drosophila.
IRAK
NF-kappa B
0
Assaying of entity1_term, complement factors, and entity2_term in the diagnosis of malignant serous effusions.
tumor necrosis factor alpha
alpha-1-antitrypsin
0
The objective of this study was to measure the concentrations of entity1_term (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, entity2_term (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.
tumor necrosis factor-alpha
alpha-1-antitrypsin
0
The objective of this study was to measure the concentrations of entity1_term (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (entity2_term), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.
tumor necrosis factor-alpha
alpha1AT
0
The objective of this study was to measure the concentrations of entity1_term (entity2_term) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.
tumor necrosis factor-alpha
TNFalpha
0
The objective of this study was to measure the concentrations of entity1_term (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether entity2_term, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.
tumor necrosis factor-alpha
TNFalpha
0
The objective of this study was to measure the concentrations of entity1_term (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors entity2_term and C4 can be used in the differential diagnosis of serous effusion.
tumor necrosis factor-alpha
C3
0
The objective of this study was to measure the concentrations of entity1_term (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and entity2_term can be used in the differential diagnosis of serous effusion.
tumor necrosis factor-alpha
C4
0
The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, entity1_term (entity2_term), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.
alpha-1-antitrypsin
alpha1AT
0
The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (entity1_term) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, entity2_term (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.
TNFalpha
alpha-1-antitrypsin
0
The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether entity1_term, entity2_term (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.
TNFalpha
alpha-1-antitrypsin
0
The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, entity1_term (alpha1AT), and complement factors entity2_term and C4 can be used in the differential diagnosis of serous effusion.
alpha-1-antitrypsin
C3
0
The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, entity1_term (alpha1AT), and complement factors C3 and entity2_term can be used in the differential diagnosis of serous effusion.
alpha-1-antitrypsin
C4
0
The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (entity1_term) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (entity2_term), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.
TNFalpha
alpha1AT
0
The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether entity1_term, alpha-1-antitrypsin (entity2_term), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.
TNFalpha
alpha1AT
0
The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (entity1_term), and complement factors entity2_term and C4 can be used in the differential diagnosis of serous effusion.
alpha1AT
C3
0
The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (entity1_term), and complement factors C3 and entity2_term can be used in the differential diagnosis of serous effusion.
alpha1AT
C4
0
The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (entity1_term) in pleural and peritoneal effusions of different causes and to verify whether entity2_term, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion.
TNFalpha
TNFalpha
0
The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (entity1_term) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors entity2_term and C4 can be used in the differential diagnosis of serous effusion.
TNFalpha
C3
0
The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (entity1_term) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and entity2_term can be used in the differential diagnosis of serous effusion.
TNFalpha
C4
0
The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether entity1_term, alpha-1-antitrypsin (alpha1AT), and complement factors entity2_term and C4 can be used in the differential diagnosis of serous effusion.
TNFalpha
C3
0
The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether entity1_term, alpha-1-antitrypsin (alpha1AT), and complement factors C3 and entity2_term can be used in the differential diagnosis of serous effusion.
TNFalpha
C4
0
entity1_term, entity2_term, and complement factors C3 and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods.
TNFalpha
alpha1AT
0
entity1_term, alpha1AT, and complement factors entity2_term and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods.
TNFalpha
C3
0
entity1_term, alpha1AT, and complement factors C3 and entity2_term concentrations were measured simultaneously in blood and serous effusion using commercially available methods.
TNFalpha
C4
0
TNFalpha, entity1_term, and complement factors entity2_term and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods.
alpha1AT
C3
0
TNFalpha, entity1_term, and complement factors C3 and entity2_term concentrations were measured simultaneously in blood and serous effusion using commercially available methods.
alpha1AT
C4
0
TNFalpha, alpha1AT, and complement factors entity1_term and entity2_term concentrations were measured simultaneously in blood and serous effusion using commercially available methods.
C3
C4
0
The objective of this study was to measure the concentrations of tumor necrosis factor-alpha (TNFalpha) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha, alpha-1-antitrypsin (alpha1AT), and complement factors entity1_term and entity2_term can be used in the differential diagnosis of serous effusion.
C3
C4
0
Their order of selection was entity1_term effusion, entity2_term serum, TNFalpha-effusion, and C3 effusion.
alpha1AT
C4
0
Their order of selection was entity1_term effusion, C4 serum, entity2_term-effusion, and C3 effusion.
alpha1AT
TNFalpha
0
Their order of selection was entity1_term effusion, C4 serum, TNFalpha-effusion, and entity2_term effusion.
alpha1AT
C3
0
Their order of selection was alpha1AT effusion, entity1_term serum, entity2_term-effusion, and C3 effusion.
C4
TNFalpha
0
Their order of selection was alpha1AT effusion, entity1_term serum, TNFalpha-effusion, and entity2_term effusion.
C4
C3
0
Their order of selection was alpha1AT effusion, C4 serum, entity1_term-effusion, and entity2_term effusion.
TNFalpha
C3
0
Determination of entity1_term, complement factors C3 and C4, and entity2_term may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.
TNFalpha
alpha1AT
0
Determination of entity1_term, complement factors entity2_term and C4, and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.
TNFalpha
C3
0
Determination of entity1_term, complement factors C3 and entity2_term, and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.
TNFalpha
C4
0
Determination of TNFalpha, complement factors entity1_term and C4, and entity2_term may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.
C3
alpha1AT
0
Determination of TNFalpha, complement factors C3 and entity1_term, and entity2_term may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.
C4
alpha1AT
0
Determination of TNFalpha, complement factors entity1_term and entity2_term, and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions, particularly in those patients with malignant disease.
C3
C4
0
Endogenous entity1_term-entity2_term complexes were detected in human CSF by immunoprecipitation.
TTR
A beta
1
Using site-directed mutagenesis and computer-assisted modelling, we identified amino acid residues on the surface of the entity1_term monomer that interact with entity2_term.
TTR
A beta
1
entity1_term (TTR), a second major CSF protein, formed SDS-stable complexes with entity2_term and significantly decreased the rate of A beta fibril formation.
Transthyretin
A beta
1
Transthyretin (entity1_term), a second major CSF protein, formed SDS-stable complexes with entity2_term and significantly decreased the rate of A beta fibril formation.
TTR
A beta
1
Interaction of entity1_term with entity2_term: binding and inhibition of amyloid formation.
transthyretin
amyloid beta-protein
1
Aggregated entity1_term (entity2_term) is a key component of the amyloid depositions found in the brains of patients with Alzheimer's disease.
amyloid beta-protein
A beta
0
The analysis of complexes of entity1_term with CSF proteins in a KBr gradient revealed an association of entity2_term only with free proteins and not with lipoprotein particles.
A beta
A beta
0
Transthyretin (TTR), a second major CSF protein, formed SDS-stable complexes with entity1_term and significantly decreased the rate of entity2_term fibril formation.
A beta
A beta
0
entity1_term (TTR), a second major CSF protein, formed SDS-stable complexes with A beta and significantly decreased the rate of entity2_term fibril formation.
Transthyretin
A beta
0
Transthyretin (entity1_term), a second major CSF protein, formed SDS-stable complexes with A beta and significantly decreased the rate of entity2_term fibril formation.
TTR
A beta
0
In physiological buffers and CSF, entity1_term exclusively decreased the level of entity2_term pentamers.
TTR
A beta
0
entity1_term (entity2_term), a second major CSF protein, formed SDS-stable complexes with A beta and significantly decreased the rate of A beta fibril formation.
Transthyretin
TTR
0
We propose that entity1_term binding proteins play a key role in the modulation of entity2_term aggregation and normally prevent amyloid formation in biological fluids and in the brain.
A beta
A beta
0
We report chemotaxis and competitive binding studies that show entity1_term binds to and activates CCR1 and entity2_term transfected HEK-293 cells.
LEC
CCR8
1
entity1_term induces chemotaxis and adhesion by interacting with CCR1 and entity2_term.
LEC
CCR8
1
We report chemotaxis and competitive binding studies that show entity1_term binds to and activates entity2_term and CCR8 transfected HEK-293 cells.
LEC
CCR1
1
entity1_term induces chemotaxis and adhesion by interacting with entity2_term and CCR8.
LEC
CCR1
1
LEC induces chemotaxis and adhesion by interacting with entity1_term and entity2_term.
CCR1
CCR8
0
Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as entity1_term, entity2_term, NCC-4, and CCL16.
LMC
HCC-4
0
entity1_term (LEC) is an unusually large CC chemokine, which is also known as entity2_term, HCC-4, NCC-4, and CCL16.
Liver-expressed chemokine
LMC
0
Liver-expressed chemokine (entity1_term) is an unusually large CC chemokine, which is also known as entity2_term, HCC-4, NCC-4, and CCL16.
LEC
LMC
0
Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as entity1_term, HCC-4, entity2_term, and CCL16.
LMC
NCC-4
0
Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as entity1_term, HCC-4, NCC-4, and entity2_term.
LMC
CCL16
0
entity1_term (LEC) is an unusually large CC chemokine, which is also known as LMC, entity2_term, NCC-4, and CCL16.
Liver-expressed chemokine
HCC-4
0
Liver-expressed chemokine (entity1_term) is an unusually large CC chemokine, which is also known as LMC, entity2_term, NCC-4, and CCL16.
LEC
HCC-4
0
Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, entity1_term, entity2_term, and CCL16.
HCC-4
NCC-4
0
Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, entity1_term, NCC-4, and entity2_term.
HCC-4
CCL16
0
entity1_term (entity2_term) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and CCL16.
Liver-expressed chemokine
LEC
0
entity1_term (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, entity2_term, and CCL16.
Liver-expressed chemokine
NCC-4
0
entity1_term (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and entity2_term.
Liver-expressed chemokine
CCL16
0
Liver-expressed chemokine (entity1_term) is an unusually large CC chemokine, which is also known as LMC, HCC-4, entity2_term, and CCL16.
LEC
NCC-4
0
Liver-expressed chemokine (entity1_term) is an unusually large CC chemokine, which is also known as LMC, HCC-4, NCC-4, and entity2_term.
LEC
CCL16
0
We report chemotaxis and competitive binding studies that show LEC binds to and activates entity1_term and entity2_term transfected HEK-293 cells.
CCR1
CCR8
0
Liver-expressed chemokine (LEC) is an unusually large CC chemokine, which is also known as LMC, HCC-4, entity1_term, and entity2_term.
NCC-4
CCL16
0
entity1_term induced maximal migration of entity2_term and CCR8 transfected cells at 89.3 nmol/L and cell adhesion at 5.6 nmol/L.
LEC
CCR1
0
entity1_term induced maximal migration of CCR1 and entity2_term transfected cells at 89.3 nmol/L and cell adhesion at 5.6 nmol/L.
LEC
CCR8
0
LEC induced maximal migration of entity1_term and entity2_term transfected cells at 89.3 nmol/L and cell adhesion at 5.6 nmol/L.
CCR1
CCR8
0
The molar concentration of entity1_term required to induce maximum cell migration is 20- to 200-fold greater than that required for entity2_term or I309, respectively.
LEC
RANTES
0
The molar concentration of entity1_term required to induce maximum cell migration is 20- to 200-fold greater than that required for RANTES or entity2_term, respectively.
LEC
I309
0
A neutralizing polyclonal antibody to LEC was developed to demonstrate that the unusually high concentration of entity1_term required to induce chemotaxis was a property of entity2_term and not as a result of an irrelevant protein contamination.
LEC
LEC
0
A neutralizing polyclonal antibody to entity1_term was developed to demonstrate that the unusually high concentration of LEC required to induce chemotaxis was a property of entity2_term and not as a result of an irrelevant protein contamination.
LEC
LEC
0
The molar concentration of LEC required to induce maximum cell migration is 20- to 200-fold greater than that required for entity1_term or entity2_term, respectively.
RANTES
I309
0
A neutralizing polyclonal antibody to entity1_term was developed to demonstrate that the unusually high concentration of entity2_term required to induce chemotaxis was a property of LEC and not as a result of an irrelevant protein contamination.
LEC
LEC
0
entity1_term protein interacts with CSB protein and with entity2_term protein, a subunit of the human RNA polymerase II transcription factor IIH.
CSA
p44
1
entity1_term protein interacts with entity2_term protein and with p44 protein, a subunit of the human RNA polymerase II transcription factor IIH.
CSA
CSB
1
The cloned CSB gene encodes a member of a protein family that includes the yeast Snf2 protein, a component of the transcriptional regulator entity1_term/entity2_term.
Swi
Snf
0
The cloned CSB gene encodes a member of a protein family that includes the yeast entity1_term protein, a component of the transcriptional regulator entity2_term/Snf.
Snf2
Swi
0
The cloned entity1_term gene encodes a member of a protein family that includes the yeast Snf2 protein, a component of the transcriptional regulator entity2_term/Snf.
CSB
Swi
0
These observations suggest that the products of the entity1_term and entity2_term genes are involved in transcription.
CSA
CSB
0
The cloned CSB gene encodes a member of a protein family that includes the yeast entity1_term protein, a component of the transcriptional regulator Swi/entity2_term.
Snf2
Snf
0
The cloned entity1_term gene encodes a member of a protein family that includes the yeast Snf2 protein, a component of the transcriptional regulator Swi/entity2_term.
CSB
Snf
0
CSA protein interacts with entity1_term protein and with entity2_term protein, a subunit of the human RNA polymerase II transcription factor IIH.
CSB
p44
0
The cloned entity1_term gene encodes a member of a protein family that includes the yeast entity2_term protein, a component of the transcriptional regulator Swi/Snf.
CSB
Snf2
0
Thus entity1_term is a cellular oncogene that targets PP2A and entity2_term, both of which are targets for oncogenic viruses and chemical tumour promoters.
HOX11
PP1
1
We observed that the protein entity1_term interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (entity2_term) in mammalian cells.
HOX11
PP1C
1
Thus entity1_term is a cellular oncogene that targets entity2_term and PP1, both of which are targets for oncogenic viruses and chemical tumour promoters.
HOX11
PP2A
1
We observed that the protein entity1_term interacted with protein serine-threonine phosphatase 2A catalytic subunit (entity2_term), as well as protein phosphatase 1 (PP1C) in mammalian cells.
HOX11
PP2AC
1
We observed that the protein entity1_term interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as entity2_term (PP1C) in mammalian cells.
HOX11
protein phosphatase 1
1
entity1_term interacts with protein phosphatases PP2A and entity2_term and disrupts a G2/M cell-cycle checkpoint.
HOX11
PP1
1
We observed that the protein entity1_term interacted with protein entity2_term (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.
HOX11
serine-threonine phosphatase 2A catalytic subunit
1
entity1_term interacts with protein phosphatases entity2_term and PP1 and disrupts a G2/M cell-cycle checkpoint.
HOX11
PP2A
1
HOX11 interacts with protein phosphatases entity1_term and entity2_term and disrupts a G2/M cell-cycle checkpoint.
PP2A
PP1
0
We observed that the protein entity1_term interacted with protein entity2_term catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.
HOX11
serine-threonine phosphatase 2A
0
We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (entity1_term), as well as entity2_term (PP1C) in mammalian cells.
PP2AC
protein phosphatase 1
0
We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (entity1_term), as well as protein phosphatase 1 (entity2_term) in mammalian cells.
PP2AC
PP1C
0
We observed that the protein HOX11 interacted with protein entity1_term catalytic subunit (entity2_term), as well as protein phosphatase 1 (PP1C) in mammalian cells.
serine-threonine phosphatase 2A
PP2AC
0
We observed that the protein HOX11 interacted with protein entity1_term (entity2_term), as well as protein phosphatase 1 (PP1C) in mammalian cells.
serine-threonine phosphatase 2A catalytic subunit
PP2AC
0
We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as entity1_term (entity2_term) in mammalian cells.
protein phosphatase 1
PP1C
0
We observed that the protein HOX11 interacted with protein entity1_term catalytic subunit (PP2AC), as well as entity2_term (PP1C) in mammalian cells.
serine-threonine phosphatase 2A
protein phosphatase 1
0
We observed that the protein HOX11 interacted with protein entity1_term (PP2AC), as well as entity2_term (PP1C) in mammalian cells.
serine-threonine phosphatase 2A catalytic subunit
protein phosphatase 1
0
We observed that the protein HOX11 interacted with protein entity1_term catalytic subunit (PP2AC), as well as protein phosphatase 1 (entity2_term) in mammalian cells.
serine-threonine phosphatase 2A
PP1C
0
We observed that the protein HOX11 interacted with protein entity1_term (PP2AC), as well as protein phosphatase 1 (entity2_term) in mammalian cells.
serine-threonine phosphatase 2A catalytic subunit
PP1C
0
We observed that the protein HOX11 interacted with protein entity1_termentity2_term (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.
serine-threonine phosphatase 2A
serine-threonine phosphatase 2A catalytic subunit
0
Thus HOX11 is a cellular oncogene that targets entity1_term and entity2_term, both of which are targets for oncogenic viruses and chemical tumour promoters.
PP2A
PP1
0
We report an interaction between the human PS1 or entity1_term hydrophilic loop and entity2_term, a small GTPase belonging to the Ras-related superfamily.
PS2
Rab11
1
Interaction domains were mapped to codons 374-400 for entity1_term and to codons 106-179 for entity2_term, a region including the fourth GTP-binding domain.
PS1
Rab11
1
We report an interaction between the human entity1_term or PS2 hydrophilic loop and entity2_term, a small GTPase belonging to the Ras-related superfamily.
PS1
Rab11
1
We report an interaction between the human entity1_term or entity2_term hydrophilic loop and Rab11, a small GTPase belonging to the Ras-related superfamily.
PS1
PS2
0
entity1_term (entity2_term) mutations account for the majority of early-onset dominant cases of familial Alzheimer's disease.
Presenilin 1
PS1
0
We have now isolated cDNA clones that contain the full-length coding sequence of two other proteins, RBP1 and entity1_term, cloned originally by their interaction with entity2_term.
RBP2
pRB
1
In addition we have been able to identify complexes of entity1_term and entity2_term in vivo that are dissociated in the presence of purified human papillomavirus E7 protein.
pRB
RBP1
1
Characterization of the entity1_term binding proteins RBP1 and entity2_term.
retinoblastoma
RBP2
1
We have now isolated cDNA clones that contain the full-length coding sequence of two other proteins, entity1_term and RBP2, cloned originally by their interaction with entity2_term.
RBP1
pRB
1
Characterization of the entity1_term binding proteins entity2_term and RBP2.
retinoblastoma
RBP1
1
Characterization of the retinoblastoma binding proteins entity1_term and entity2_term.
RBP1
RBP2
0
The entity1_term gene product, entity2_term, regulates cell proliferation by binding to and inhibiting the activity of key growth promoting proteins.
retinoblastoma
pRB
0
The products of the entity1_term and entity2_term genes are ubiquitously expressed, large (200 kDa for RBP1 and 195 kDa for RBP2) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.
RBP1
RBP2
0
The products of the entity1_term and RBP2 genes are ubiquitously expressed, large (200 kDa for entity2_term and 195 kDa for RBP2) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.
RBP1
RBP1
0
The products of the entity1_term and RBP2 genes are ubiquitously expressed, large (200 kDa for RBP1 and 195 kDa for entity2_term) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.
RBP1
RBP2
0
The products of the RBP1 and entity1_term genes are ubiquitously expressed, large (200 kDa for entity2_term and 195 kDa for RBP2) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.
RBP2
RBP1
0
The products of the RBP1 and entity1_term genes are ubiquitously expressed, large (200 kDa for RBP1 and 195 kDa for entity2_term) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.
RBP2
RBP2
0
We have now isolated cDNA clones that contain the full-length coding sequence of two other proteins, entity1_term and entity2_term, cloned originally by their interaction with pRB.
RBP1
RBP2
0
The products of the RBP1 and RBP2 genes are ubiquitously expressed, large (200 kDa for entity1_term and 195 kDa for entity2_term) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.
RBP1
RBP2
0
In addition we have been able to identify complexes of entity1_term and RBP1 in vivo that are dissociated in the presence of purified human papillomavirus entity2_term protein.
pRB
E7
0
In addition we have been able to identify complexes of pRB and entity1_term in vivo that are dissociated in the presence of purified human papillomavirus entity2_term protein.
RBP1
E7
0
RANTES interacts with CCR5 and entity1_term with entity2_term receptors.
SDF-1
CXCR4
1
entity1_term interacts with entity2_term and SDF-1 with CXCR4 receptors.
RANTES
CCR5
1
RANTES interacts with entity1_term and entity2_term with CXCR4 receptors.
CCR5
SDF-1
0
RANTES interacts with entity1_term and SDF-1 with entity2_term receptors.
CCR5
CXCR4
0
entity1_term interacts with CCR5 and entity2_term with CXCR4 receptors.
RANTES
SDF-1
0
DCs express more entity1_term and entity2_term mRNA than T cells.
CCR5
CXCR4
0
entity1_term interacts with CCR5 and SDF-1 with entity2_term receptors.
RANTES
CXCR4
0
We now find that HIV-1 begins reverse transcription much more efficiently in DCs than T cells, even though T cells have higher levels of entity1_term and entity2_term binding.
CD4
gp120
0
A van't Hoff plot of the change in Kd was linear between 10 and 37 degrees C and yielded values of DeltaH degrees = -12.9 kcal/mol and DeltaS degrees = -15.9 cal mol-1 deg-1, suggesting that electrostatic forces play a prominent role in the interaction of entity1_term with entity2_term.
C8
C9
1
Native entity1_term also formed a heterodimer with entity2_term,and low concentrations of polyionic ligands such as protamine and suramin inhibited the interaction.
C8
C5
1
Native entity1_term and entity2_term formed a heterodimer in solution of physiological ionic strength with a free-energy change DeltaG degrees of -8.3 kcal/mol and a dissociation constant Kd of 0.6 microM (at 20 degrees C) that was ionic strength- and temperature-dependent.
C8
C9
1
Suramin induced high-affinity trimerization of entity1_term (Kd = 0.10 microM at 20 degrees C) and dimerization of entity2_term (Kd = 0.86 microM at 20 degrees C).
C8
C9
0
Analysis of sedimentation equilibria and also of the fluorescence enhancement of suramin when bound to protein provided evidence for two suramin-binding sites on each entity1_term and three on each entity2_term in the oligomers.
C9
C8
0
In yeast, entity1_term interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and entity2_term, but not with Cdk4.
Cdi1
Cdk3
1
In HeLa cells, entity1_term is expressed at the G1 to S transition, and the protein forms stable complexes with entity2_term.
Cdi1
Cdk2
1
In yeast, entity1_term interacts with cyclin-dependent kinases, including human entity2_term, Cdk2, and Cdk3, but not with Cdk4.
Cdi1
Cdc2
1
In yeast, entity1_term interacts with cyclin-dependent kinases, including human Cdc2, entity2_term, and Cdk3, but not with Cdk4.
Cdi1
Cdk2
1
entity1_term, a human G1 and S phase protein phosphatase that associates with entity2_term.
Cdi1
Cdk2
1
We used the interaction trap, a yeast genetic selection for interacting proteins, to isolate human entity1_term (entity2_term).
cyclin-dependent kinase interactor 1
Cdi1
0
In yeast, Cdi1 interacts with cyclin-dependent kinases, including human entity1_term, entity2_term, and Cdk3, but not with Cdk4.
Cdc2
Cdk2
0
In yeast, Cdi1 interacts with cyclin-dependent kinases, including human entity1_term, Cdk2, and entity2_term, but not with Cdk4.
Cdc2
Cdk3
0
In yeast, Cdi1 interacts with cyclin-dependent kinases, including human entity1_term, Cdk2, and Cdk3, but not with entity2_term.
Cdc2
Cdk4
0
In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, entity1_term, and entity2_term, but not with Cdk4.
Cdk2
Cdk3
0
In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, entity1_term, and Cdk3, but not with entity2_term.
Cdk2
Cdk4
0
In yeast, entity1_term interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with entity2_term.
Cdi1
Cdk4
0
In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and entity1_term, but not with entity2_term.
Cdk3
Cdk4
0
Overexpression of wild-type entity1_term delays progression through the cell cycle in yeast and HeLa cells; delay is dependent on entity2_term phosphatase activity.
Cdi1
Cdi1
0
The entity1_term-entity2_term complex suggests a binding site for transferrin on TfR and sheds light upon the function of HFE in regulating iron homeostasis.
HFE
TfR
1
On a cell membrane containing both proteins, HFE would 'lie down' parallel to the membrane, such that the entity1_term helices that delineate the counterpart of the MHC peptide-binding groove make extensive contacts with helices in the entity2_term dimerization domain.
HFE
TfR
1
The structures of entity1_term alone and complexed with entity2_term differ in their domain arrangement and dimer interfaces, providing a mechanism for communicating binding events between TfR chains.
TfR
HFE
1
The 2.8 A crystal structure of a complex between the extracellular portions of entity1_term and entity2_term shows two HFE molecules which grasp each side of a twofold symmetric TfR dimer.
HFE
TfR
1
The 2.8 A crystal structure of a complex between the extracellular portions of HFE and TfR shows two entity1_term molecules which grasp each side of a twofold symmetric entity2_term dimer.
HFE
TfR
1
entity1_term binds to the entity2_term (TfR), a receptor by which cells acquire iron-loaded transferrin.
HFE
transferrin receptor
1
entity1_term binds to the transferrin receptor (entity2_term), a receptor by which cells acquire iron-loaded transferrin.
HFE
TfR
1
Crystal structure of the hereditary haemochromatosis protein entity1_term complexed with entity2_term.
HFE
transferrin receptor
1
Crystal structure of the hereditary haemochromatosis protein entity1_term complexed with entity2_term receptor.
HFE
transferrin
0
Crystal structure of the hereditary haemochromatosis protein HFE complexed with entity1_termentity2_term receptor.
transferrin receptor
transferrin
0
HFE binds to the entity1_termentity2_term (TfR), a receptor by which cells acquire iron-loaded transferrin.
transferrin
transferrin receptor
0
entity1_term binds to the entity2_term receptor (TfR), a receptor by which cells acquire iron-loaded transferrin.
HFE
transferrin
0
HFE binds to the entity1_term receptor (entity2_term), a receptor by which cells acquire iron-loaded transferrin.
transferrin
TfR
0
HFE binds to the entity1_term receptor (TfR), a receptor by which cells acquire iron-loaded entity2_term.
transferrin
transferrin
0
HFE binds to the entity1_term (entity2_term), a receptor by which cells acquire iron-loaded transferrin.
transferrin receptor
TfR
0
HFE binds to the entity1_term (TfR), a receptor by which cells acquire iron-loaded entity2_term.
transferrin receptor
transferrin
0
entity1_term binds to the transferrin receptor (TfR), a receptor by which cells acquire iron-loaded entity2_term.
HFE
transferrin
0
The 2.8 A crystal structure of a complex between the extracellular portions of entity1_term and TfR shows two entity2_term molecules which grasp each side of a twofold symmetric TfR dimer.
HFE
HFE
0
The 2.8 A crystal structure of a complex between the extracellular portions of entity1_term and TfR shows two HFE molecules which grasp each side of a twofold symmetric entity2_term dimer.
HFE
TfR
0
The 2.8 A crystal structure of a complex between the extracellular portions of HFE and entity1_term shows two entity2_term molecules which grasp each side of a twofold symmetric TfR dimer.
TfR
HFE
0
The 2.8 A crystal structure of a complex between the extracellular portions of HFE and entity1_term shows two HFE molecules which grasp each side of a twofold symmetric entity2_term dimer.
TfR
TfR
0
HFE binds to the transferrin receptor (entity1_term), a receptor by which cells acquire iron-loaded entity2_term.
TfR
transferrin
0
On a cell membrane containing both proteins, entity1_term would 'lie down' parallel to the membrane, such that the entity2_term helices that delineate the counterpart of the MHC peptide-binding groove make extensive contacts with helices in the TfR dimerization domain.
HFE
HFE
0
On a cell membrane containing both proteins, entity1_term would 'lie down' parallel to the membrane, such that the HFE helices that delineate the counterpart of the MHC peptide-binding groove make extensive contacts with helices in the entity2_term dimerization domain.
HFE
TfR
0
The HFE-TfR complex suggests a binding site for transferrin on entity1_term and sheds light upon the function of entity2_term in regulating iron homeostasis.
TfR
HFE
0
The HFE-entity1_term complex suggests a binding site for transferrin on TfR and sheds light upon the function of entity2_term in regulating iron homeostasis.
TfR
HFE
0
The entity1_term-TfR complex suggests a binding site for transferrin on TfR and sheds light upon the function of entity2_term in regulating iron homeostasis.
HFE
HFE
0
The structures of entity1_term alone and complexed with HFE differ in their domain arrangement and dimer interfaces, providing a mechanism for communicating binding events between entity2_term chains.
TfR
TfR
0
The HFE-entity1_term complex suggests a binding site for transferrin on entity2_term and sheds light upon the function of HFE in regulating iron homeostasis.
TfR
TfR
0
The entity1_term-TfR complex suggests a binding site for transferrin on entity2_term and sheds light upon the function of HFE in regulating iron homeostasis.
HFE
TfR
0
The structures of TfR alone and complexed with entity1_term differ in their domain arrangement and dimer interfaces, providing a mechanism for communicating binding events between entity2_term chains.
HFE
TfR
0
We found that deletion of the carboxyl-terminal 28 amino acids of PU.1 disrupted entity1_term-entity2_term physical interaction.
PU.1
NF-IL6 beta
1
We have characterized the physical and functional interactions between entity1_term and entity2_term, a leucine zipper transcription factor implicated in inflammatory responses.
PU.1
NF-IL6 beta
1
Transcriptional synergy with entity1_term (C/entity2_term, CRP3).
NF-IL6 beta
EBP delta
0
Transcriptional synergy with NF-IL6 beta (C/entity1_term, entity2_term).
EBP delta
CRP3
0
Transcriptional synergy with entity1_term (C/EBP delta, entity2_term).
NF-IL6 beta
CRP3
0
Using radiolabeled entity1_term protein as a probe, we screened a B cell cDNA expression library and isolated a number of clones encoding entity2_term interacting proteins.
PU.1
PU.1
0
Three of these clones encode DNA binding proteins (NF-IL6 beta, entity1_term, and entity2_term), one clone encodes a chaperone protein, and another clone encodes a multifunctional phosphatase.
HMG I/Y
SSRP
0
Three of these clones encode DNA binding proteins (entity1_term, entity2_term, and SSRP), one clone encodes a chaperone protein, and another clone encodes a multifunctional phosphatase.
NF-IL6 beta
HMG I/Y
0
Three of these clones encode DNA binding proteins (entity1_term, HMG I/Y, and entity2_term), one clone encodes a chaperone protein, and another clone encodes a multifunctional phosphatase.
NF-IL6 beta
SSRP
0
We found that deletion of the carboxyl-terminal 28 amino acids of entity1_term disrupted entity2_term-NF-IL6 beta physical interaction.
PU.1
PU.1
0
We found that deletion of the carboxyl-terminal 28 amino acids of entity1_term disrupted PU.1-entity2_term physical interaction.
PU.1
NF-IL6 beta
0
Electrophoretic mobility shift assays showed that entity1_term and entity2_term can simultaneously bind to adjacent DNA binding sites, but apparently do not influence the kinetics or affinity of each other's DNA binding.
PU.1
NF-IL6 beta
0
In transient expression assays, we found that entity1_term and entity2_term can functionally cooperate to synergistically activate transcription.
PU.1
NF-IL6 beta
0
The gamma chain of the entity1_termentity2_term) receptor is shared with the functional IL-4 receptor and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.
interleukin-2 (IL-2) receptor
IL-2
0
The gamma chain of the entity1_term (entity2_term) receptor is shared with the functional IL-4 receptor and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.
interleukin-2
IL-2
0
The gamma chain of the interleukin-2 (entity1_term) receptor is shared with the functional entity2_term receptor and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.
IL-2
IL-4
0
The gamma chain of the interleukin-2 (entity1_term) receptor is shared with the functional entity2_term and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.
IL-2
IL-4 receptor
0
The gamma chain of the entity1_termentity2_term (IL-2) receptor is shared with the functional IL-4 receptor and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.
interleukin-2 (IL-2) receptor
interleukin-2
0
The gamma chain of the entity1_term is shared with the functional entity2_term receptor and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.
interleukin-2 (IL-2) receptor
IL-4
0
The gamma chain of the entity1_term is shared with the functional entity2_term and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.
interleukin-2 (IL-2) receptor
IL-4 receptor
0
Functional participation of the entity1_term receptor gamma chain in entity2_term complexes.
IL-2
IL-7 receptor
0
Functional participation of the IL-2 receptor gamma chain in entity1_termentity2_term receptor complexes.
IL-7 receptor
IL-7
0
Functional participation of the entity1_term chain in entity2_term complexes.
IL-2 receptor gamma
IL-7 receptor
0
Studies with monoclonal antibodies specific for the entity1_term receptor gamma chain showed that the gamma chain participates in the functional high-affinity receptor complexes for entity2_term that are involved in the differentiation of T and B cells.
IL-2
IL-7
0
The gamma chain of the entity1_term (IL-2) receptor is shared with the functional entity2_term receptor and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.
interleukin-2
IL-4
0
The gamma chain of the entity1_term (IL-2) receptor is shared with the functional entity2_term and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.
interleukin-2
IL-4 receptor
0
The gamma chain of the interleukin-2 (IL-2) receptor is shared with the functional entity1_termentity2_term and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect.
IL-4
IL-4 receptor
0
Functional participation of the entity1_term receptor gamma chain in entity2_term receptor complexes.
IL-2
IL-7
0
Functional participation of the entity1_termentity2_term chain in IL-7 receptor complexes.
IL-2
IL-2 receptor gamma
0
Functional participation of the entity1_term chain in entity2_term receptor complexes.
IL-2 receptor gamma
IL-7
0
A large epitope 1 for high-affinity entity1_term binding was detected spanning the interface of the entity2_term dimer.
BMPR-IA
BMP-2
1
The binding epitopes of entity1_term for BMPR-IA (type I) and entity2_term or ActR-II (type II) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains.
BMP-2
BMPR-II
1
The binding epitopes of entity1_term for BMPR-IA (type I) and BMPR-II or entity2_term (type II) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains.
BMP-2
ActR-II
1
The binding epitopes of entity1_term for entity2_term (type I) and BMPR-II or ActR-II (type II) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains.
BMP-2
BMPR-IA
1
entity1_term antagonists emerge from alterations in the low-affinity binding epitope for receptor entity2_term.
BMP-2
BMPR-II
0
entity1_term (entity2_term) induces bone formation and regeneration in adult vertebrates and regulates important developmental processes in all animals.
Bone morphogenetic protein-2
BMP-2
0
BMP-2 is a homodimeric cysteine knot protein that, as a member of the entity1_term (entity2_term) superfamily, signals by oligomerizing type I and type II receptor serine-kinases in the cell membrane.
transforming growth factor-beta
TGF-beta
0
entity1_term is a homodimeric cysteine knot protein that, as a member of the entity2_term (TGF-beta) superfamily, signals by oligomerizing type I and type II receptor serine-kinases in the cell membrane.
BMP-2
transforming growth factor-beta
0
entity1_term is a homodimeric cysteine knot protein that, as a member of the transforming growth factor-beta (entity2_term) superfamily, signals by oligomerizing type I and type II receptor serine-kinases in the cell membrane.
BMP-2
TGF-beta
0
The binding epitopes of BMP-2 for BMPR-IA (type I) and entity1_term or entity2_term (type II) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains.
BMPR-II
ActR-II
0
The binding epitopes of BMP-2 for BMPR-IA (type I) and entity1_term or ActR-II (type II) were characterized using entity2_term mutant proteins for analysis of interactions with receptor ectodomains.
BMPR-II
BMP-2
0
The binding epitopes of BMP-2 for entity1_term (type I) and entity2_term or ActR-II (type II) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains.
BMPR-IA
BMPR-II
0
The binding epitopes of BMP-2 for BMPR-IA (type I) and BMPR-II or entity1_term (type II) were characterized using entity2_term mutant proteins for analysis of interactions with receptor ectodomains.
ActR-II
BMP-2
0
The binding epitopes of BMP-2 for entity1_term (type I) and BMPR-II or entity2_term (type II) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains.
BMPR-IA
ActR-II
0
The binding epitopes of entity1_term for BMPR-IA (type I) and BMPR-II or ActR-II (type II) were characterized using entity2_term mutant proteins for analysis of interactions with receptor ectodomains.
BMP-2
BMP-2
0
The binding epitopes of BMP-2 for entity1_term (type I) and BMPR-II or ActR-II (type II) were characterized using entity2_term mutant proteins for analysis of interactions with receptor ectodomains.
BMPR-IA
BMP-2
0
The screen identified interactions involving entity1_term and two 14-3-3 isoforms, cytokeratin 18, human unconventional myosin IC, and a recently identified SH3 domain containing protein, entity2_term.
c-Cbl
SH3 P17
1
The precise function of c-Cbl in these pathways is not clear, although a genetic analysis in Caenorhabditis elegans suggests that entity1_term is a negative regulator of the entity2_term.
c-Cbl
epidermal growth factor receptor
1
The screen identified interactions involving entity1_term and two 14-3-3 isoforms, entity2_term, human unconventional myosin IC, and a recently identified SH3 domain containing protein, SH3 P17.
c-Cbl
cytokeratin 18
1
The protein product of entity1_term proto-oncogene is known to interact with several proteins, including Grb2, entity2_term and PI3 kinase, and is thought to regulate signalling by many cell surface receptors.
c-cbl
Crk
1
The protein product of entity1_term proto-oncogene is known to interact with several proteins, including Grb2, Crk and entity2_term, and is thought to regulate signalling by many cell surface receptors.
c-cbl
PI3 kinase
1
The protein product of entity1_term proto-oncogene is known to interact with several proteins, including entity2_term, Crk and PI3 kinase, and is thought to regulate signalling by many cell surface receptors.
c-cbl
Grb2
1
The protein product of c-cbl proto-oncogene is known to interact with several proteins, including entity1_term, entity2_term and PI3 kinase, and is thought to regulate signalling by many cell surface receptors.
Grb2
Crk
0
The protein product of c-cbl proto-oncogene is known to interact with several proteins, including entity1_term, Crk and entity2_term, and is thought to regulate signalling by many cell surface receptors.
Grb2
PI3 kinase
0
The precise function of entity1_term in these pathways is not clear, although a genetic analysis in Caenorhabditis elegans suggests that entity2_term is a negative regulator of the epidermal growth factor receptor.
c-Cbl
c-Cbl
0
The precise function of entity1_term in these pathways is not clear, although a genetic analysis in Caenorhabditis elegans suggests that c-Cbl is a negative regulator of the entity2_term receptor.
c-Cbl
epidermal growth factor
0
The precise function of entity1_term in these pathways is not clear, although a genetic analysis in Caenorhabditis elegans suggests that c-Cbl is a negative regulator of the entity2_term.
c-Cbl
epidermal growth factor receptor
0
The precise function of c-Cbl in these pathways is not clear, although a genetic analysis in Caenorhabditis elegans suggests that entity1_term is a negative regulator of the entity2_term receptor.
c-Cbl
epidermal growth factor
0
The protein product of c-cbl proto-oncogene is known to interact with several proteins, including Grb2, entity1_term and entity2_term, and is thought to regulate signalling by many cell surface receptors.
Crk
PI3 kinase
0
The screen identified interactions involving c-Cbl and two 14-3-3 isoforms, entity1_term, human unconventional myosin IC, and a recently identified SH3 domain containing protein, entity2_term.
cytokeratin 18
SH3 P17
0
The precise function of c-Cbl in these pathways is not clear, although a genetic analysis in Caenorhabditis elegans suggests that c-Cbl is a negative regulator of the entity1_termentity2_term.
epidermal growth factor
epidermal growth factor receptor
0
Moreover, a transcriptional activation signal was transduced by entity1_term in the presence of type I receptors after stimulation by entity2_term/BMP-7.
BMPR-II
OP-1
1
Moreover, a transcriptional activation signal was transduced by entity1_term in the presence of type I receptors after stimulation by OP-1/entity2_term.
BMPR-II
BMP-7
1
Binding of entity1_term/BMP-7 to entity2_term was also observed in nontransfected cell lines.
OP-1
BMPR-II
1
Binding of OP-1/entity1_term to entity2_term was also observed in nontransfected cell lines.
BMP-7
BMPR-II
1
In transfected COS-1 cells, osteogenic protein (OP)-1/entity1_term, and less efficiently BMP-4, bound to entity2_term.
BMP-7
BMPR-II
1
In transfected COS-1 cells, osteogenic protein (OP)-1/BMP-7, and less efficiently entity1_term, bound to entity2_term.
BMP-4
BMPR-II
1
In transfected COS-1 cells, entity1_term/BMP-7, and less efficiently BMP-4, bound to entity2_term.
osteogenic protein (OP)-1
BMPR-II
1
Here we report the cDNA cloning and characterization of a human type II receptor for BMPs (entity1_term), which is distantly related to entity2_term, a BMP type II receptor from Caenorhabditis elegans.
BMPR-II
DAF-4
0
Here we report the cDNA cloning and characterization of a human type II receptor for BMPs (BMPR-II), which is distantly related to entity1_term, a entity2_term from Caenorhabditis elegans.
DAF-4
BMP type II receptor
0
Here we report the cDNA cloning and characterization of a human type II receptor for BMPs (entity1_term), which is distantly related to DAF-4, a entity2_term from Caenorhabditis elegans.
BMPR-II
BMP type II receptor
0
In transfected COS-1 cells, osteogenic protein (OP)-1/entity1_term, and less efficiently entity2_term, bound to BMPR-II.
BMP-7
BMP-4
0
In transfected COS-1 cells, entity1_term/entity2_term, and less efficiently BMP-4, bound to BMPR-II.
osteogenic protein (OP)-1
BMP-7
0
In transfected COS-1 cells, entity1_term/BMP-7, and less efficiently entity2_term, bound to BMPR-II.
osteogenic protein (OP)-1
BMP-4
0
Binding of entity1_term/entity2_term to BMPR-II was also observed in nontransfected cell lines.
OP-1
BMP-7
0
Moreover, a transcriptional activation signal was transduced by BMPR-II in the presence of type I receptors after stimulation by entity1_term/entity2_term.
OP-1
BMP-7
0
The cell surface form of entity1_term is assembled during biosynthesis as a heteromeric complex with lymphotoxin-beta (entity2_term), a type II transmembrane protein that is another member of the TNF ligand family.
LT-alpha
LT-beta
1
Secreted LT-alpha is a homotrimer that binds to distinct TNF receptors of 60 and 80 kilodaltons; however, these receptors do not recognize the major cell surface entity1_term-entity2_term complex.
LT-alpha
LT-beta
1
The cell surface form of entity1_term is assembled during biosynthesis as a heteromeric complex with entity2_term (LT-beta), a type II transmembrane protein that is another member of the TNF ligand family.
LT-alpha
lymphotoxin-beta
1
The cell surface form of LT-alpha is assembled during biosynthesis as a heteromeric complex with entity1_term (entity2_term), a type II transmembrane protein that is another member of the TNF ligand family.
lymphotoxin-beta
LT-beta
0
Secreted entity1_term is a homotrimer that binds to distinct TNF receptors of 60 and 80 kilodaltons; however, these receptors do not recognize the major cell surface entity2_term-LT-beta complex.
LT-alpha
LT-alpha
0
Secreted entity1_term is a homotrimer that binds to distinct TNF receptors of 60 and 80 kilodaltons; however, these receptors do not recognize the major cell surface LT-alpha-entity2_term complex.
LT-alpha
LT-beta
0
A receptor specific for human entity1_term was identified, which suggests that cell surface LT may have functions that are distinct from those of secreted entity2_term.
LT-beta
LT-alpha
0
Tumor necrosis factor (TNF) and entity1_term (entity2_term) are members of a family of secreted and cell surface cytokines that participate in the regulation of immune and inflammatory responses.
lymphotoxin-alpha
LT-alpha
0
We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain (referred to as entity1_term binding protein, entity2_term) of the EPOR.
EPO
EBP
1
Mutagenesis of the entity1_term receptor (entity2_term) permits analysis of the contribution that individual amino acid residues make to erythropoietin (EPO) binding.
erythropoietin
EPOR
1
Mutagenesis studies of the human entity1_termentity2_term.
erythropoietin
erythropoietin receptor
0
Mutagenesis of the entity1_term receptor (EPOR) permits analysis of the contribution that individual amino acid residues make to entity2_term (EPO) binding.
erythropoietin
erythropoietin
0
Mutagenesis of the entity1_term receptor (EPOR) permits analysis of the contribution that individual amino acid residues make to erythropoietin (entity2_term) binding.
erythropoietin
EPO
0
Mutagenesis of the entity1_termentity2_term (EPOR) permits analysis of the contribution that individual amino acid residues make to erythropoietin (EPO) binding.
erythropoietin
erythropoietin receptor
0
Mutagenesis of the erythropoietin receptor (EPOR) permits analysis of the contribution that individual amino acid residues make to entity1_term (entity2_term) binding.
erythropoietin
EPO
0
Mutagenesis of the entity1_term (EPOR) permits analysis of the contribution that individual amino acid residues make to entity2_term (EPO) binding.
erythropoietin receptor
erythropoietin
0
Mutagenesis of the erythropoietin receptor (entity1_term) permits analysis of the contribution that individual amino acid residues make to entity2_term (EPO) binding.
EPOR
erythropoietin
0
Mutagenesis of the entity1_term (EPOR) permits analysis of the contribution that individual amino acid residues make to erythropoietin (entity2_term) binding.
erythropoietin receptor
EPO
0
Mutagenesis of the erythropoietin receptor (entity1_term) permits analysis of the contribution that individual amino acid residues make to erythropoietin (entity2_term) binding.
EPOR
EPO
0
Mutagenesis of the entity1_term (entity2_term) permits analysis of the contribution that individual amino acid residues make to erythropoietin (EPO) binding.
erythropoietin receptor
EPOR
0
We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain (referred to as EPO binding protein, entity1_term) of the entity2_term.
EBP
EPOR
0
We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain (referred to as entity1_term, entity2_term) of the EPOR.
EPO binding protein
EBP
0
We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain (referred to as entity1_term binding protein, EBP) of the entity2_term.
EPO
EPOR
0
We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain (referred to as entity1_term, EBP) of the entity2_term.
EPO binding protein
EPOR
0
Site-specific mutants were expressed in Escherichia coli as soluble entity1_term and analyzed for entity2_term binding in several different assay formats.
EBP
EPO
0
We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain (referred to as entity1_termentity2_term, EBP) of the EPOR.
EPO
EPO binding protein
0
In addition, selected mutant proteins were expressed as full-length entity1_term on the surface of COS cells and analyzed for 125I-entity2_term binding in receptor binding assays.
EPOR
EPO
0
Using these methods, we have identified residues that appear to be involved in entity1_term binding as well as other residues, most of which are conserved in receptors of the cytokine receptor family, that appear to be necessary for the proper folding and/or stability of the entity2_term.
EPO
EPOR
0
The SH2/SH3 domain-containing protein entity1_term interacts with tyrosine-phosphorylated entity2_term and Shc: implications for insulin control of ras signalling.
GRB2
IRS1
1
We propose a model whereby insulin stimulation leads to formation of multiple protein--protein interactions between entity1_term and the two targets IRS-1 and entity2_term.
GRB2
Shc
1
Interestingly, both GRB2 and entity1_term can simultaneously bind distinct tyrosine phosphorylated regions on the same entity2_term molecule, suggesting a mechanism whereby IRS-1 could provide the core for a large signalling complex.
phosphatidylinositol-3 (PI-3) kinase
IRS-1
1
We propose a model whereby insulin stimulation leads to formation of multiple protein--protein interactions between entity1_term and the two targets entity2_term and Shc.
GRB2
IRS-1
1
Interestingly, both entity1_term and phosphatidylinositol-3 (PI-3) kinase can simultaneously bind distinct tyrosine phosphorylated regions on the same entity2_term molecule, suggesting a mechanism whereby IRS-1 could provide the core for a large signalling complex.
GRB2
IRS-1
1
Furthermore, we have identified a short sequence motif (YV/IN) present in IRS-1, entity1_term and Shc, which specifically binds the SH2 domain of entity2_term with high affinity.
EGFR
GRB2
1
Furthermore, we have identified a short sequence motif (YV/IN) present in IRS-1, EGFR and entity1_term, which specifically binds the SH2 domain of entity2_term with high affinity.
Shc
GRB2
1
Although entity1_term associates with IRS-1 and entity2_term, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.
GRB2
Shc
1
Furthermore, we have identified a short sequence motif (YV/IN) present in entity1_term, EGFR and Shc, which specifically binds the SH2 domain of entity2_term with high affinity.
IRS-1
GRB2
1
The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of entity1_term to phosphotyrosines on both IRS-1 and entity2_term.
GRB2
Shc
1
Although entity1_term associates with entity2_term and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.
GRB2
IRS-1
1
The SH2/SH3 domain-containing protein entity1_term interacts with tyrosine-phosphorylated IRS1 and entity2_term: implications for insulin control of ras signalling.
GRB2
Shc
1
The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of entity1_term to phosphotyrosines on both entity2_term and Shc.
GRB2
IRS-1
1
entity1_term, a small protein comprising one SH2 domain and two SH3 domains, represents the human homologue of the Caenorhabditis elegans protein, entity2_term.
GRB2
sem-5
0
Both entity1_term and entity2_term have been implicated in a highly conserved mechanism that regulates p21ras signalling by receptor tyrosine kinases.
GRB2
sem-5
0
Both entity1_term and sem-5 have been implicated in a highly conserved mechanism that regulates entity2_term signalling by receptor tyrosine kinases.
GRB2
p21ras
0
The SH2/SH3 domain-containing protein entity1_term interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of entity2_term signalling.
GRB2
ras
0
The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and entity1_term: implications for insulin control of entity2_term signalling.
Shc
ras
0
The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated entity1_term and Shc: implications for insulin control of entity2_term signalling.
IRS1
ras
0
Interestingly, both entity1_term and entity2_term can simultaneously bind distinct tyrosine phosphorylated regions on the same IRS-1 molecule, suggesting a mechanism whereby IRS-1 could provide the core for a large signalling complex.
GRB2
phosphatidylinositol-3 (PI-3) kinase
0
Interestingly, both GRB2 and entity1_term can simultaneously bind distinct tyrosine phosphorylated regions on the same IRS-1 molecule, suggesting a mechanism whereby entity2_term could provide the core for a large signalling complex.
phosphatidylinositol-3 (PI-3) kinase
IRS-1
0
Interestingly, both entity1_term and phosphatidylinositol-3 (PI-3) kinase can simultaneously bind distinct tyrosine phosphorylated regions on the same IRS-1 molecule, suggesting a mechanism whereby entity2_term could provide the core for a large signalling complex.
GRB2
IRS-1
0
Both GRB2 and entity1_term have been implicated in a highly conserved mechanism that regulates entity2_term signalling by receptor tyrosine kinases.
sem-5
p21ras
0
Furthermore, we have identified a short sequence motif (YV/IN) present in IRS-1, entity1_term and entity2_term, which specifically binds the SH2 domain of GRB2 with high affinity.
EGFR
Shc
0
Furthermore, we have identified a short sequence motif (YV/IN) present in entity1_term, EGFR and entity2_term, which specifically binds the SH2 domain of GRB2 with high affinity.
IRS-1
Shc
0
Furthermore, we have identified a short sequence motif (YV/IN) present in entity1_term, entity2_term and Shc, which specifically binds the SH2 domain of GRB2 with high affinity.
IRS-1
EGFR
0
Although GRB2 associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after entity1_term stimulation, implying that entity2_term is not a substrate for the insulin receptor.
insulin
GRB2
0
Although GRB2 associates with IRS-1 and entity1_term, it is not tyrosine-phosphorylated after insulin stimulation, implying that entity2_term is not a substrate for the insulin receptor.
Shc
GRB2
0
Although GRB2 associates with entity1_term and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that entity2_term is not a substrate for the insulin receptor.
IRS-1
GRB2
0
Although entity1_term associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that entity2_term is not a substrate for the insulin receptor.
GRB2
GRB2
0
Although GRB2 associates with IRS-1 and entity1_term, it is not tyrosine-phosphorylated after entity2_term stimulation, implying that GRB2 is not a substrate for the insulin receptor.
Shc
insulin
0
Although GRB2 associates with entity1_term and Shc, it is not tyrosine-phosphorylated after entity2_term stimulation, implying that GRB2 is not a substrate for the insulin receptor.
IRS-1
insulin
0
Although entity1_term associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after entity2_term stimulation, implying that GRB2 is not a substrate for the insulin receptor.
GRB2
insulin
0
Although GRB2 associates with entity1_term and entity2_term, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.
IRS-1
Shc
0
The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated entity1_term and entity2_term: implications for insulin control of ras signalling.
IRS1
Shc
0
In this report we show that in response to entity1_term, entity2_term forms a stable complex with two tyrosine-phosphorylated proteins.
insulin
GRB2
0
One protein is the major insulin receptor substrate entity1_term and the second is the SH2 domain-containing oncogenic protein, entity2_term.
IRS-1
Shc
0
The interactions between entity1_term and these two proteins require ligand activation of the entity2_term and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and Shc.
GRB2
insulin receptor
0
The interactions between entity1_term and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of entity2_term to phosphotyrosines on both IRS-1 and Shc.
GRB2
GRB2
0
The interactions between entity1_term and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both entity2_term and Shc.
GRB2
IRS-1
0
The interactions between entity1_term and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and entity2_term.
GRB2
Shc
0
We propose a model whereby insulin stimulation leads to formation of multiple protein--protein interactions between GRB2 and the two targets entity1_term and entity2_term.
IRS-1
Shc
0
The interactions between GRB2 and these two proteins require ligand activation of the entity1_term and are mediated by the binding of the SH2 domain of entity2_term to phosphotyrosines on both IRS-1 and Shc.
insulin receptor
GRB2
0
The interactions between GRB2 and these two proteins require ligand activation of the entity1_term and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both entity2_term and Shc.
insulin receptor
IRS-1
0
The interactions between GRB2 and these two proteins require ligand activation of the entity1_term and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and entity2_term.
insulin receptor
Shc
0
The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both entity1_term and entity2_term.
IRS-1
Shc
0
Interestingly, both GRB2 and phosphatidylinositol-3 (PI-3) kinase can simultaneously bind distinct tyrosine phosphorylated regions on the same entity1_term molecule, suggesting a mechanism whereby entity2_term could provide the core for a large signalling complex.
IRS-1
IRS-1
0
Recombinant entity1_term binds directly to entity2_term both in vitro and in yeast, and participates in the formation of the TFIID complex.
hTAFII250
TBP
1
Biochemical studies established that some coactivators are associated with the entity1_term (entity2_term) to form the TFIID complex.
TATA-binding protein
TBP
0
Biochemical studies established that some coactivators are associated with the entity1_term (TBP) to form the entity2_term complex.
TATA-binding protein
TFIID
0
Biochemical studies established that some coactivators are associated with the TATA-binding protein (entity1_term) to form the entity2_term complex.
TBP
TFIID
0
Recombinant entity1_term binds directly to TBP both in vitro and in yeast, and participates in the formation of the entity2_term complex.
hTAFII250
TFIID
0
Recombinant hTAFII250 binds directly to entity1_term both in vitro and in yeast, and participates in the formation of the entity2_term complex.
TBP
TFIID
0
The entity1_term gene is identical to a gene, entity2_term, (ref 7,8), implicated in cell-cycle progression.
hTAFII250
CCG1
0
This largest TAF may therefore play a central role in entity1_term assembly by interacting with both entity2_term and other TAFs, as well as serving to link the control of transcription to the cell cycle.
TFIID
TBP
0
Based on the structure of the closely related lymphotoxin alpha-tumor necrosis factor receptor I complex, a molecular model of the entity1_term homotrimer bound to three entity2_term molecules was generated using knowledge-based protein modeling methods.
FasL
Fas
1
Although the cytotoxic activity of mutant Y218D was unaltered, mutant Y218R was inactive, correlating with the prediction that Tyr-218 of entity1_term interacts with a cluster of three basic amino acid side chains of entity2_term.
FasL
Fas
1
The death-inducing receptor Fas is activated when cross-linked by the type II membrane protein entity1_term ligand (entity2_term).
Fas
FasL
1
Based on the structure of the closely related entity1_term-entity2_term complex, a molecular model of the FasL homotrimer bound to three Fas molecules was generated using knowledge-based protein modeling methods.
lymphotoxin alpha
tumor necrosis factor receptor I
1
The death-inducing receptor entity1_term is activated when cross-linked by the type II membrane protein entity2_term (FasL).
Fas
Fas ligand
1
The death-inducing receptor entity1_term is activated when cross-linked by the type II membrane protein Fas ligand (entity2_term).
Fas
FasL
1
Characterization of Fas (entity1_term, CD95)-entity2_term interaction.
Apo-1
Fas ligand
1
Characterization of Fas (Apo-1, entity1_term)-entity2_term interaction.
CD95
Fas ligand
1
Characterization of entity1_term (Apo-1, CD95)-entity2_term interaction.
Fas
Fas ligand
1
Characterization of entity1_term (Apo-1, entity2_term)-Fas ligand interaction.
Fas
CD95
0
Characterization of entity1_term (entity2_term, CD95)-Fas ligand interaction.
Fas
Apo-1
0
Characterization of entity1_term (Apo-1, CD95)-entity2_term ligand interaction.
Fas
Fas
0
Characterization of Fas (entity1_term, entity2_term)-Fas ligand interaction.
Apo-1
CD95
0
Characterization of Fas (Apo-1, entity1_term)-entity2_term ligand interaction.
CD95
Fas
0
Characterization of Fas (entity1_term, CD95)-entity2_term ligand interaction.
Apo-1
Fas
0
The death-inducing receptor entity1_term is activated when cross-linked by the type II membrane protein entity2_term ligand (FasL).
Fas
Fas
0
The death-inducing receptor Fas is activated when cross-linked by the type II membrane protein entity1_termentity2_term (FasL).
Fas
Fas ligand
0
Characterization of Fas (Apo-1, CD95)-entity1_termentity2_term interaction.
Fas
Fas ligand
0
When human soluble entity1_term (sFasL, containing the extracellular portion) was expressed in human embryo kidney 293 cells, the three N-linked glycans of each entity2_term monomer were found to be essential for efficient secretion.
FasL
FasL
0
Based on the structure of the closely related entity1_term-tumor necrosis factor receptor I complex, a molecular model of the entity2_term homotrimer bound to three Fas molecules was generated using knowledge-based protein modeling methods.
lymphotoxin alpha
FasL
0
Based on the structure of the closely related entity1_term-tumor necrosis factor receptor I complex, a molecular model of the FasL homotrimer bound to three entity2_term molecules was generated using knowledge-based protein modeling methods.
lymphotoxin alpha
Fas
0
The death-inducing receptor Fas is activated when cross-linked by the type II membrane protein entity1_term (entity2_term).
Fas ligand
FasL
0
Based on the structure of the closely related lymphotoxin alpha-entity1_term complex, a molecular model of the entity2_term homotrimer bound to three Fas molecules was generated using knowledge-based protein modeling methods.
tumor necrosis factor receptor I
FasL
0
Based on the structure of the closely related lymphotoxin alpha-entity1_term complex, a molecular model of the FasL homotrimer bound to three entity2_term molecules was generated using knowledge-based protein modeling methods.
tumor necrosis factor receptor I
Fas
0
Mutants P206R, P206D, and P206F displayed reduced cytotoxicity toward entity1_term-positive cells with a concomitant decrease in the binding affinity for the recombinant entity2_term-immunoglobulin Fc fusion proteins.
Fas
Fas
0
Unlabeled entity1_term and TNF-beta were equally effective at displacing the binding of labeled entity2_term to TNF-R expressing cells.
TNF-alpha
TNF-alpha
0
Unlabeled TNF-alpha and entity1_term were equally effective at displacing the binding of labeled entity2_term to TNF-R expressing cells.
TNF-beta
TNF-alpha
0
Unlabeled entity1_term and entity2_term were equally effective at displacing the binding of labeled TNF-alpha to TNF-R expressing cells.
TNF-alpha
TNF-beta
0
The extracellular cysteine-rich domain of the TNF-R is homologous to the nerve growth factor receptor and the entity1_term entity2_term.
B cell activation protein
Bp50
0
Scatchard analysis of in vitro binding between Raf/330 and G beta gamma revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between entity1_term and entity2_term (Kd = 87 +/- 24 nM).
G beta gamma
beta ARK
1
In vivo complexes of entity1_term and entity2_term were isolated from human embryonic kidney 293-T cells transfected with epitope-tagged G beta 2.
Raf-1
G beta gamma
1
In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the entity1_term-binding proteins, entity2_term and 14-3-3, had no effect.
Raf-1
Ras
1
Scatchard analysis of in vitro binding between entity1_term and entity2_term revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between G beta gamma and beta ARK (Kd = 87 +/- 24 nM).
Raf/330
G beta gamma
1
In vitro, purified entity1_term subunits specifically bound to a GST fusion protein encoding amino acids 1-330 of Raf-1 (entity2_term).
G beta gamma
Raf/330
1
In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of entity1_term to entity2_term; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.
G beta gamma
Raf/330
1
Using a yeast two-hybrid strategy to identify other proteins that interact with and potentially regulate entity1_term, we isolated a clone encoding the carboxyl-terminal half of the entity2_term of heterotrimeric G-proteins.
Raf-1
G beta 2 subunit
1
In vitro, purified entity1_term subunits specifically bound to a GST fusion protein encoding amino acids 1-330 of entity2_term (Raf/330).
G beta gamma
Raf-1
1
A direct interaction between entity1_term subunits and the entity2_term.
G-protein beta gamma
Raf-1 protein kinase
1
Raf-1 is a serine/threonine protein kinase positioned downstream of entity1_term in the entity2_term cascade.
Ras
mitogen-activated protein kinase
0
entity1_term is a serine/threonine protein kinase positioned downstream of entity2_term in the mitogen-activated protein kinase cascade.
Raf-1
Ras
0
entity1_term is a serine/threonine protein kinase positioned downstream of Ras in the entity2_term cascade.
Raf-1
mitogen-activated protein kinase
0
In vivo complexes of Raf-1 and entity1_term were isolated from human embryonic kidney 293-T cells transfected with epitope-tagged entity2_term.
G beta gamma
G beta 2
0
In vivo complexes of entity1_term and G beta gamma were isolated from human embryonic kidney 293-T cells transfected with epitope-tagged entity2_term.
Raf-1
G beta 2
0
In vitro, purified G beta gamma subunits specifically bound to a GST fusion protein encoding amino acids 1-330 of entity1_term (entity2_term).
Raf-1
Raf/330
0
The formation of native heterotrimeric entity1_term complexes, as measured by pertussis toxin ADP-ribosylation of G alpha, could be disrupted by increasing amounts of entity2_term, with an EC50 of approximately 200 nM, in close agreement with the estimated binding affinity.
G alpha beta gamma
Raf/330
0
Scatchard analysis of in vitro binding between Raf/330 and entity1_term revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between G beta gamma and entity2_term (Kd = 87 +/- 24 nM).
G beta gamma
beta ARK
0
Scatchard analysis of in vitro binding between entity1_term and G beta gamma revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between G beta gamma and entity2_term (Kd = 87 +/- 24 nM).
Raf/330
beta ARK
0
Scatchard analysis of in vitro binding between Raf/330 and entity1_term revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between entity2_term and beta ARK (Kd = 87 +/- 24 nM).
G beta gamma
G beta gamma
0
Scatchard analysis of in vitro binding between entity1_term and G beta gamma revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between entity2_term and beta ARK (Kd = 87 +/- 24 nM).
Raf/330
G beta gamma
0
Binding assays with truncation mutants of GST-entity1_term indicate that the region located between amino acids 136 and 239 is a primary determinant for interaction with entity2_term.
Raf
G beta gamma
0
In competition experiments, the carboxyl terminus of entity1_term (entity2_term) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.
beta-adrenergic receptor kinase
beta ARK
0
In competition experiments, the carboxyl terminus of entity1_term (beta ARK) blocked the binding of entity2_term to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.
beta-adrenergic receptor kinase
G beta gamma
0
In competition experiments, the carboxyl terminus of entity1_term (beta ARK) blocked the binding of G beta gamma to entity2_term; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.
beta-adrenergic receptor kinase
Raf/330
0
In competition experiments, the carboxyl terminus of entity1_term (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the entity2_term-binding proteins, Ras and 14-3-3, had no effect.
beta-adrenergic receptor kinase
Raf-1
0
In competition experiments, the carboxyl terminus of entity1_term (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, entity2_term and 14-3-3, had no effect.
beta-adrenergic receptor kinase
Ras
0
In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (entity1_term) blocked the binding of entity2_term to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.
beta ARK
G beta gamma
0
In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (entity1_term) blocked the binding of G beta gamma to entity2_term; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.
beta ARK
Raf/330
0
In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (entity1_term) blocked the binding of G beta gamma to Raf/330; however, the entity2_term-binding proteins, Ras and 14-3-3, had no effect.
beta ARK
Raf-1
0
In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (entity1_term) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, entity2_term and 14-3-3, had no effect.
beta ARK
Ras
0
In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of entity1_term to Raf/330; however, the entity2_term-binding proteins, Ras and 14-3-3, had no effect.
G beta gamma
Raf-1
0
In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of entity1_term to Raf/330; however, the Raf-1-binding proteins, entity2_term and 14-3-3, had no effect.
G beta gamma
Ras
0
In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to entity1_term; however, the entity2_term-binding proteins, Ras and 14-3-3, had no effect.
Raf/330
Raf-1
0
In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to entity1_term; however, the Raf-1-binding proteins, entity2_term and 14-3-3, had no effect.
Raf/330
Ras
0
These data show that entity1_term and entity2_term physically and functionally interact demonstrating that cross-talk occurs between factors of distantly related transcription families.
USF
Fra1
1
Both the bHLHZip and the N-terminal regions of entity1_term are required for efficient interaction with entity2_term.
Fra1
USF
1
In vivo association between entity1_term and entity2_term has been demonstrated by co-immunoprecipitation.
USF
Fra1
1
A bZip protein, entity1_term, was found to efficiently interact with entity2_term.
Fra1
USF
1
entity1_term specifically interacts with entity2_term but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.
USF
Fra1
1
Cross-family interaction between the bHLHZip entity1_term and bZip entity2_term proteins results in down-regulation of AP1 activity.
USF
Fra1
1
Cross-family interaction between the bHLHZip entity1_term and bZip Fra1 proteins results in down-regulation of entity2_term activity.
USF
AP1
0
Cross-family interaction between the bHLHZip USF and bZip entity1_term proteins results in down-regulation of entity2_term activity.
Fra1
AP1
0
To further examine the function of the bHLHZip protein, entity1_term, we screened for cellular proteins which could directly interact with entity2_term using the yeast two-hybrid system.
USF
USF
0
USF specifically interacts with Fra1 but not with other closely related family members, entity1_term, entity2_term, FosB, or with c-Jun.
c-Fos
Fra2
0
USF specifically interacts with Fra1 but not with other closely related family members, entity1_term, Fra2, entity2_term, or with c-Jun.
c-Fos
FosB
0
entity1_term specifically interacts with Fra1 but not with other closely related family members, entity2_term, Fra2, FosB, or with c-Jun.
USF
c-Fos
0
USF specifically interacts with Fra1 but not with other closely related family members, entity1_term, Fra2, FosB, or with entity2_term.
c-Fos
c-Jun
0
USF specifically interacts with entity1_term but not with other closely related family members, entity2_term, Fra2, FosB, or with c-Jun.
Fra1
c-Fos
0
USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, entity1_term, entity2_term, or with c-Jun.
Fra2
FosB
0
entity1_term specifically interacts with Fra1 but not with other closely related family members, c-Fos, entity2_term, FosB, or with c-Jun.
USF
Fra2
0
USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, entity1_term, FosB, or with entity2_term.
Fra2
c-Jun
0
USF specifically interacts with entity1_term but not with other closely related family members, c-Fos, entity2_term, FosB, or with c-Jun.
Fra1
Fra2
0
entity1_term specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, entity2_term, or with c-Jun.
USF
FosB
0
USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, entity1_term, or with entity2_term.
FosB
c-Jun
0
USF specifically interacts with entity1_term but not with other closely related family members, c-Fos, Fra2, entity2_term, or with c-Jun.
Fra1
FosB
0
entity1_term specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with entity2_term.
USF
c-Jun
0
USF specifically interacts with entity1_term but not with other closely related family members, c-Fos, Fra2, FosB, or with entity2_term.
Fra1
c-Jun
0
Expression of exogenous entity1_term led to a decrease in entity2_term-dependent transcription in F9 cells.
USF
AP1
0
Co-expression of exogenous entity1_term restored the entity2_term activity in a dose-dependent manner.
Fra1
AP1
0
When transfected into COS cells the cloned cDNA directed the expression of a entity1_term showing a single class of affinity (KD = 2(-8) nM) and specificity for human entity2_term but not interleukin-3.
GM-CSF-R
GM-CSF
1
Two cDNA clones encoding a receptor for human entity1_term (entity2_term) were isolated by expression screening of a library made from human placental mRNA.
granulocyte-macrophage colony-stimulating factor
hGM-CSF-R
1
It does not contain a tyrosine kinase domain nor show homology with members of the immunoglobulin super gene family, but does show some significant sequence homologies with receptors for several other haemopoietic growth factors, including those for entity1_term, erythropoietin and entity2_term (beta-chain) and also to the prolactin receptor.
interleukin-6
interleukin-2
0
It does not contain a tyrosine kinase domain nor show homology with members of the immunoglobulin super gene family, but does show some significant sequence homologies with receptors for several other haemopoietic growth factors, including those for interleukin-6, entity1_term and entity2_term (beta-chain) and also to the prolactin receptor.
erythropoietin
interleukin-2
0
When transfected into COS cells the cloned cDNA directed the expression of a entity1_term showing a single class of affinity (KD = 2(-8) nM) and specificity for human GM-CSF but not entity2_term.
GM-CSF-R
interleukin-3
0
It does not contain a tyrosine kinase domain nor show homology with members of the immunoglobulin super gene family, but does show some significant sequence homologies with receptors for several other haemopoietic growth factors, including those for entity1_term, entity2_term and interleukin-2 (beta-chain) and also to the prolactin receptor.
interleukin-6
erythropoietin
0
When transfected into COS cells the cloned cDNA directed the expression of a GM-CSF-R showing a single class of affinity (KD = 2(-8) nM) and specificity for human entity1_term but not entity2_term.
GM-CSF
interleukin-3
0
Association of entity1_term with both entity2_term and HSP90 may also imply a mechanistic link between the functions of CDC37 and HSP90.
CDK4
CDC37
1
Association of entity1_term with both CDC37 and entity2_term may also imply a mechanistic link between the functions of CDC37 and HSP90.
CDK4
HSP90
1
A physical interaction between entity1_term and entity2_term suggests that CDC37 may regulate the mammalian cell cycle through a direct effect on CDK4.
CDC37
CDK4
1
A physical interaction between CDC37 and CDK4 suggests that entity1_term may regulate the mammalian cell cycle through a direct effect on entity2_term.
CDC37
CDK4
1
We have detected a specific association of entity1_term with the molecular chaperon entity2_term and a 44-kDa protein that we identify as mammalian CDC37.
CDK4
HSP90
1
We have detected a specific association of entity1_term with the molecular chaperon HSP90 and a 44-kDa protein that we identify as mammalian entity2_term.
CDK4
CDC37
1
Physical interaction of mammalian entity1_term with entity2_term .CDC37 was originally identified as a Start gene in budding yeast and has been shown to be required for association of CDC28 with cyclins.
CDC37
CDK4
1
Physical interaction of mammalian entity1_term with CDK4 entity2_term was originally identified as a Start gene in budding yeast and has been shown to be required for association of CDC28 with cyclins.
CDC37
.CDC37
0
Physical interaction of mammalian entity1_term with CDK4 .CDC37 was originally identified as a Start gene in budding yeast and has been shown to be required for association of entity2_term with cyclins.
CDC37
CDC28
0
Physical interaction of mammalian CDC37 with entity1_term entity2_term was originally identified as a Start gene in budding yeast and has been shown to be required for association of CDC28 with cyclins.
CDK4
.CDC37
0
Physical interaction of mammalian CDC37 with CDK4 entity1_term was originally identified as a Start gene in budding yeast and has been shown to be required for association of entity2_term with cyclins.
.CDC37
CDC28
0
Physical interaction of mammalian CDC37 with entity1_term .CDC37 was originally identified as a Start gene in budding yeast and has been shown to be required for association of entity2_term with cyclins.
CDK4
CDC28
0
entity1_term is a entity2_term that controls progression through G1 of the mammalian cell cycle.
CDK4
cyclin D-dependent kinase
0
We have detected a specific association of CDK4 with the molecular chaperon entity1_term and a 44-kDa protein that we identify as mammalian entity2_term.
HSP90
CDC37
0
A physical interaction between entity1_term and CDK4 suggests that entity2_term may regulate the mammalian cell cycle through a direct effect on CDK4.
CDC37
CDC37
0
A physical interaction between entity1_term and CDK4 suggests that CDC37 may regulate the mammalian cell cycle through a direct effect on entity2_term.
CDC37
CDK4
0
A physical interaction between CDC37 and entity1_term suggests that entity2_term may regulate the mammalian cell cycle through a direct effect on CDK4.
CDK4
CDC37
0
A physical interaction between CDC37 and entity1_term suggests that CDC37 may regulate the mammalian cell cycle through a direct effect on entity2_term.
CDK4
CDK4
0
Association of entity1_term with both CDC37 and HSP90 may also imply a mechanistic link between the functions of entity2_term and HSP90.
CDK4
CDC37
0
Association of entity1_term with both CDC37 and HSP90 may also imply a mechanistic link between the functions of CDC37 and entity2_term.
CDK4
HSP90
0
Association of CDK4 with both entity1_term and entity2_term may also imply a mechanistic link between the functions of CDC37 and HSP90.
CDC37
HSP90
0
Association of CDK4 with both entity1_term and HSP90 may also imply a mechanistic link between the functions of entity2_term and HSP90.
CDC37
CDC37
0
Association of CDK4 with both entity1_term and HSP90 may also imply a mechanistic link between the functions of CDC37 and entity2_term.
CDC37
HSP90
0
Association of CDK4 with both CDC37 and entity1_term may also imply a mechanistic link between the functions of entity2_term and HSP90.
HSP90
CDC37
0
Association of CDK4 with both CDC37 and entity1_term may also imply a mechanistic link between the functions of CDC37 and entity2_term.
HSP90
HSP90
0
Association of CDK4 with both CDC37 and HSP90 may also imply a mechanistic link between the functions of entity1_term and entity2_term.
CDC37
HSP90
0
Comparison of the two crystallographically distinct protein-DNA complexes show that the coiled-coil is flexibly joined to the basic regions and that the entity1_term-entity2_term heterodimer does not recognize the asymmetric 5'-TGAGTCA-3' recognition element in a unique orientation.
Fos
Jun
1
The entity1_term and entity2_term families of eukaryotic transcription factors heterodimerize to form complexes capable of binding 5'-TGAGTCA-3' DNA elements.
Fos
Jun
1
We have determined the X-ray crystal structure of a heterodimer of the bZIP regions of entity1_term and entity2_term bound to DNA.
c-Fos
c-Jun
1
Crystal structure of the heterodimeric bZIP transcription factor entity1_term-entity2_term bound to DNA.
c-Fos
c-Jun
1
Moreover, mutation of entity1_term residues 143-145 impairs binding of 14-3-3, but not entity2_term, to the Raf-CRD.
Raf-1
Ras
1
Moreover, mutation of entity1_term residues 143-145 impairs binding of 14-3-3, but not Ras, to the entity2_term.
Raf-1
Raf-CRD
1
We recently reported that entity1_term interaction with the Raf-1 cysteine-rich domain (entity2_term, residues 139-184) may be required for Raf-1 activation.
Ras
Raf-CRD
1
In the present study, we demonstrate that entity1_term binds directly to the isolated entity2_term.
14-3-3 zeta
Raf-CRD
1
entity1_term negatively regulates raf-1 activity by interactions with the entity2_term cysteine-rich domain.
14-3-3 zeta
Raf-1
1
We recently reported that entity1_term interaction with the entity2_term (Raf-CRD, residues 139-184) may be required for Raf-1 activation.
Ras
Raf-1 cysteine-rich domain
1
entity1_term negatively regulates entity2_term activity by interactions with the Raf-1 cysteine-rich domain.
14-3-3 zeta
raf-1
1
Although Raf-1 is a critical effector of Ras signaling and transformation, the mechanism by which entity1_term promotes entity2_term activation is complex and remains poorly understood.
Ras
Raf-1
0
Although entity1_term is a critical effector of Ras signaling and transformation, the mechanism by which entity2_term promotes Raf-1 activation is complex and remains poorly understood.
Raf-1
Ras
0
Although Raf-1 is a critical effector of entity1_term signaling and transformation, the mechanism by which entity2_term promotes Raf-1 activation is complex and remains poorly understood.
Ras
Ras
0
Although entity1_term is a critical effector of Ras signaling and transformation, the mechanism by which Ras promotes entity2_term activation is complex and remains poorly understood.
Raf-1
Raf-1
0
Although Raf-1 is a critical effector of entity1_term signaling and transformation, the mechanism by which Ras promotes entity2_term activation is complex and remains poorly understood.
Ras
Raf-1
0
Although entity1_term is a critical effector of entity2_term signaling and transformation, the mechanism by which Ras promotes Raf-1 activation is complex and remains poorly understood.
Raf-1
Ras
0
Thus, 14-3-3 interaction with the Raf-CRD may serve in negative regulation of Raf-1 function by facilitating dissociation of 14-3-3 from the NH2 terminus of entity1_term to promote subsequent events necessary for full activation of entity2_term.
Raf-1
Raf-1
0
Thus, 14-3-3 interaction with the Raf-CRD may serve in negative regulation of entity1_term function by facilitating dissociation of 14-3-3 from the NH2 terminus of Raf-1 to promote subsequent events necessary for full activation of entity2_term.
Raf-1
Raf-1
0
Thus, 14-3-3 interaction with the entity1_term may serve in negative regulation of Raf-1 function by facilitating dissociation of 14-3-3 from the NH2 terminus of Raf-1 to promote subsequent events necessary for full activation of entity2_term.
Raf-CRD
Raf-1
0
Thus, 14-3-3 interaction with the Raf-CRD may serve in negative regulation of entity1_term function by facilitating dissociation of 14-3-3 from the NH2 terminus of entity2_term to promote subsequent events necessary for full activation of Raf-1.
Raf-1
Raf-1
0
Thus, 14-3-3 interaction with the entity1_term may serve in negative regulation of Raf-1 function by facilitating dissociation of 14-3-3 from the NH2 terminus of entity2_term to promote subsequent events necessary for full activation of Raf-1.
Raf-CRD
Raf-1
0
We recently reported that entity1_term interaction with the entity2_term cysteine-rich domain (Raf-CRD, residues 139-184) may be required for Raf-1 activation.
Ras
Raf-1
0
We recently reported that entity1_term interaction with the Raf-1 cysteine-rich domain (Raf-CRD, residues 139-184) may be required for entity2_term activation.
Ras
Raf-1
0
Thus, 14-3-3 interaction with the entity1_term may serve in negative regulation of entity2_term function by facilitating dissociation of 14-3-3 from the NH2 terminus of Raf-1 to promote subsequent events necessary for full activation of Raf-1.
Raf-CRD
Raf-1
0
We recently reported that Ras interaction with the entity1_termentity2_term (Raf-CRD, residues 139-184) may be required for Raf-1 activation.
Raf-1
Raf-1 cysteine-rich domain
0
We recently reported that Ras interaction with the entity1_term cysteine-rich domain (entity2_term, residues 139-184) may be required for Raf-1 activation.
Raf-1
Raf-CRD
0
We recently reported that Ras interaction with the entity1_term cysteine-rich domain (Raf-CRD, residues 139-184) may be required for entity2_term activation.
Raf-1
Raf-1
0
Moreover, mutation of Raf-1 residues 143-145 impairs binding of 14-3-3, but not entity1_term, to the entity2_term.
Ras
Raf-CRD
0
14-3-3 zeta negatively regulates entity1_term activity by interactions with the entity2_term cysteine-rich domain.
raf-1
Raf-1
0
We recently reported that Ras interaction with the entity1_term (entity2_term, residues 139-184) may be required for Raf-1 activation.
Raf-1 cysteine-rich domain
Raf-CRD
0
We recently reported that Ras interaction with the entity1_term (Raf-CRD, residues 139-184) may be required for entity2_term activation.
Raf-1 cysteine-rich domain
Raf-1
0
We recently reported that Ras interaction with the Raf-1 cysteine-rich domain (entity1_term, residues 139-184) may be required for entity2_term activation.
Raf-CRD
Raf-1
0
The entity1_term is located in the NH2-terminal negative regulatory domain of entity2_term and is highly homologous to cysteine-rich domains found in protein kinase C family members.
Raf-CRD
Raf-1
0
Recent studies indicate that the structural integrity of the entity1_term is also critical for entity2_term interaction with 14-3-3 proteins.
Raf-CRD
Raf-1
0
However, whether 14-3-3 proteins interact directly with the entity1_term and how this interaction may mediate entity2_term function has not been determined.
Raf-CRD
Raf-1
0
This protein, designated entity1_term (VRP), specifically binds to the extracellular domain of entity2_term, stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.
VEGF-related protein
Flt4
1
This protein, designated VEGF-related protein (entity1_term), specifically binds to the extracellular domain of entity2_term, stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.
VRP
Flt4
1
Flt1 and entity1_term have been shown to play key roles in vascular development; these two receptors bind and are activated by entity2_term (VEGF).
Flk1
vascular endothelial growth factor
1
Flt1 and entity1_term have been shown to play key roles in vascular development; these two receptors bind and are activated by vascular endothelial growth factor (entity2_term).
Flk1
VEGF
1
entity1_term and Flk1 have been shown to play key roles in vascular development; these two receptors bind and are activated by entity2_term (VEGF).
Flt1
vascular endothelial growth factor
1
entity1_term and Flk1 have been shown to play key roles in vascular development; these two receptors bind and are activated by vascular endothelial growth factor (entity2_term).
Flt1
VEGF
1
entity1_term: a ligand and specific activator of the tyrosine kinase receptor entity2_term.
Vascular endothelial growth factor-related protein
Flt4
1
entity1_term-related protein: a ligand and specific activator of the tyrosine kinase receptor entity2_term.
Vascular endothelial growth factor
Flt4
0
entity1_termentity2_term: a ligand and specific activator of the tyrosine kinase receptor Flt4.
Vascular endothelial growth factor
Vascular endothelial growth factor-related protein
0
The tyrosine kinases Flt4, Flt1, and entity1_term (or entity2_term) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain.
Flk1
KDR
0
The tyrosine kinases entity1_term, Flt1, and entity2_term (or KDR) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain.
Flt4
Flk1
0
The tyrosine kinases Flt4, entity1_term, and entity2_term (or KDR) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain.
Flt1
Flk1
0
The tyrosine kinases entity1_term, Flt1, and Flk1 (or entity2_term) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain.
Flt4
KDR
0
The tyrosine kinases Flt4, entity1_term, and Flk1 (or entity2_term) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain.
Flt1
KDR
0
The tyrosine kinases entity1_term, entity2_term, and Flk1 (or KDR) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain.
Flt4
Flt1
0
Flt1 and Flk1 have been shown to play key roles in vascular development; these two receptors bind and are activated by entity1_term (entity2_term).
vascular endothelial growth factor
VEGF
0
entity1_term and entity2_term have been shown to play key roles in vascular development; these two receptors bind and are activated by vascular endothelial growth factor (VEGF).
Flt1
Flk1
0
This protein, designated entity1_termentity2_term (VRP), specifically binds to the extracellular domain of Flt4, stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.
VEGF
VEGF-related protein
0
This protein, designated entity1_term-related protein (entity2_term), specifically binds to the extracellular domain of Flt4, stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.
VEGF
VRP
0
This protein, designated entity1_term-related protein (VRP), specifically binds to the extracellular domain of entity2_term, stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.
VEGF
Flt4
0
This protein, designated entity1_term-related protein (VRP), specifically binds to the extracellular domain of Flt4, stimulates the tyrosine phosphorylation of entity2_term expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.
VEGF
Flt4
0
This protein, designated entity1_term (entity2_term), specifically binds to the extracellular domain of Flt4, stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.
VEGF-related protein
VRP
0
This protein, designated entity1_term (VRP), specifically binds to the extracellular domain of Flt4, stimulates the tyrosine phosphorylation of entity2_term expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.
VEGF-related protein
Flt4
0
This protein, designated VEGF-related protein (entity1_term), specifically binds to the extracellular domain of Flt4, stimulates the tyrosine phosphorylation of entity2_term expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.
VRP
Flt4
0
This protein, designated VEGF-related protein (VRP), specifically binds to the extracellular domain of entity1_term, stimulates the tyrosine phosphorylation of entity2_term expressed in mammalian cells, and promotes the mitogenesis of human lung endothelial cells.
Flt4
Flt4
0
entity1_term fails to bind appreciably to the extracellular domain of Flt1 or entity2_term.
VRP
Flk1
0
VRP fails to bind appreciably to the extracellular domain of entity1_term or entity2_term.
Flt1
Flk1
0
entity1_term fails to bind appreciably to the extracellular domain of entity2_term or Flk1.
VRP
Flt1
0
